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Abstract 
In combination with chemotherapy or radiation, passive immunotherapy with monoclonal 
antibodies is state of the art in cancer therapy. For this purpose, two properties of antibodies 
are harnessed: i) via the Fab fragment they bind a specific tumour antigen and ii) via the Fc 
portion they recruit effector cells and activate the complement system. One of these 
antibodies is trastuzumab (Herceptin®), a growth-inhibitory humanized monoclonal IgG1 
antibody recognizing the tumour antigen HER-2, which is overexpressed in 30% of human 
breast cancers. Interestingly, all antibodies applied for passive immunotherapy are so far 
exclusively of the IgG subclass. 
In contrast, antibodies of the IgE subclass are best-known for their detrimental function in 
type I hypersensitivity. It is little-known that IgE has anti-tumour capacity which could be 
exploited for immunotherapy of cancer. Thus, the aim of this doctoral thesis was to examine 
alternative strategies for cancer treatment based on IgE antibodies, and to compare their 
efficacy with that of IgG.  
The oral immunization route is well suited for the induction of a Th2 immunity including high 
affine IgE responses to administered antigens. Therefore, the establishment of an IgE-
dependent food allergy model in mice is described, which we applied also for our cancer 
studies. When mice were fed with different concentrations of ovalbumin under concomitant 
anti-acid medication, an antigen-specific IgE induction in a Th2 environment could be 
achieved. This oral vaccination regimen was also used for feeding HER-2 mimotopes, i.e. 
epitope-mimics of the anti-HER-2 IgG antibody trastuzumab. Indeed, these mimotopes 
induced IgE antibodies recognizing the tumour antigen which were able to bind HER-2 
overexpressing breast cancer cells and led to tumour cell lysis. Complementary to this active 
immunotherapeutic approach a trastuzumab-like IgE antibody for passive immunotherapy was 
constructed. We could show that this trastuzumab IgE exhibited the same specificity as the 
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original trastuzumab IgG. Moreover, a three-colour flow cytometric assay indicated that even 
though both antibodies were able to induce tumour cell killing, they used different 
mechanisms: trastuzumab IgG acted via antibody-dependent cell-mediated phagocytosis 
(ADCP), whereas trastuzumab IgE elicited mostly antibody-dependent cell-mediated 
cytotoxicity (ADCC). 
Based on the presented data we conclude that tumour-specific IgE, induced actively or 
applied in a passive manner, represents a potent alternative to IgG-based immunotherapies 
against cancer.   
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Zusammenfassung 
Ergänzend zu Chemotherapie und Strahlentherapie ist die passive Immuntherapie mit 
monoklonalen Antikörpern eine moderne Behandlungsmethode in der Krebstherapie. Zwei 
Eigenschaften von Antikörpern werden dabei genutzt: i) über das Fab Fragment binden sie 
spezifisch Tumorantigene und ii) über den Fc Teil rekrutieren sie Effektorzellen und 
aktivieren das Komplementsystem. Einer dieser Antikörper ist Trastuzumab (Herceptin®), ein 
wachstumshemmender, humanisierter, monoklonaler IgG1 Antikörper. Trastuzumab ist gegen 
das Tumorantigen HER-2 gerichtet, welches in 30% aller Brusttumore überexprimiert wird. 
Alle Antikörper, die bis jetzt in Form von passiver Immuntherapie in der Klinik eingesetzt 
werden, sind ausschließlich der IgG Subklasse zu zuordnen. 
Antikörper der IgE Subklasse sind hingegen bekannt für ihre schädliche Funktion in der Typ I 
Allergie. Es ist jedoch kaum bekannt, dass IgE Antikörper eine anti-Tumor Wirkung haben 
und diese Eigenschaft für Immuntherapien in der Onkologie ausgenutzt werden könnte. Das 
Ziel dieser Doktorarbeit war es daher alternative Strategien zur Behandlung von 
Krebserkrankungen basierend auf IgE Antikörper zu untersuchen, sowie deren Wirksamkeit 
mit der von IgG zu vergleichen. 
Die orale Immunisierungsroute eignet sich sehr gut zur Induktion einer Th2 Immunantwort 
mit hoch affinen IgE Antikörpern, die gegen das applizierte Antigen gerichtet sind. Daher 
wird die Etablierung eines IgE-abhängiges Nahrungsmittelallergiemodells in Mäusen 
beschrieben. Dieses Modell haben wir anschließend für unsere Krebsstudien adaptiert. Mäuse 
wurden mit unterschiedlichen Konzentrationen von Ovalbumin unter gleichzeitiger 
Säuresuppression gefüttert. Dies führte zu einer Induktion von antigen-spezifischen IgE in 
einem Th2 Milieu. Dieses orale Immunisierungsschema wurde auch mit HER-2 Mimotopen, 
d.h. Peptide, die das Trastuzumab-Epitop imitieren, angewendet. Die durch das Mimotop 
induzierten IgE Antikörper erkannten spezifisch das Tumorantigen auf HER-2 
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überexprimierende Brustkrebszellen und führten zur Lyse der Tumorzellen. Ergänzend zu 
diesem aktiven immuntherapeutischen Ansatz wurde ein Trastuzumab IgE Antikörper für 
passive Immuntherapie konstruiert. Wir konnten zeigen, dass Trastuzumab IgE die gleiche 
Spezifität wie Trastuzumab IgG besitzt. In einem Three-Colour Flow Cytometric Assay zeigte 
sich, dass beide Antikörper Tumorzellen erfolgreich zerstören, dies aber durch 
unterschiedliche Mechanismen tun: Trastuzumab IgG führte zu „antibody-dependent cell-
mediated phagocytosis“ (ADCP), während Trastuzumab IgE „antibody-dependent cell-
mediated cytotoxicity“ (ADCC) auslöste.  
Ausgehend von den hier präsentierten Daten schließen wir, dass tumor-spezifisches IgE, aktiv 
induziert oder passiv verabreicht, eine vielversprechende Alternative zu Immuntherapien mit 
IgG gegen Krebs darstellt. 
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CHAPTER I 
Introduction part I 
1. Carcinogenesis 
Carcinogenesis in humans is a multistep process reflecting genetic alterations that drive the 
progressive transformation of normal human cells into highly malignant derivates [1]. 
Douglas Hanahan and Robert A. Weinberg proposed six capabilities shared by most and 
perhaps all types of human malignancies: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis [2]. Dunn et al. suggested a seventh 
hallmark of cancer, “immunoediting”, which makes tumours capable to escape from control 
mechanisms of the immune system. This process is divided into three phases: elimination 
(cancer immunosurveillance), equilibrium (cancer persistence) and escape (cancer 
progression). The immune system differentiates between self versus pathogen and non-self, 
but also between self and transformed self. However, the immune system does not only 
protect the host against tumour development, it also forms the immunogenic phenotype of the 
developing tumour. Therefore the term “immunoediting” describes in an appropriate way the 
two functions of the immune system during carcinogenesis [3].  
In our opinion the fact that the immune system is involved in tumourigenesis gives an 
optimistic perspective for immunological anti-cancer therapy. By exploiting immune 
mechanisms we can target and specifically destroy malignant cells while sparing normal cells. 
In contrast, chemotherapeutic drugs impair mitosis of predominantly fast-dividing cells, but 
do not differentiate between malignant and normal cells. Therefore they cause numerous side 
effects, such as derogating the immune system.  
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Significant gains in cancer therapeutics have been made in the last decade. More potent, less 
toxic derivates of classic chemotherapeutic agents have been developed and dosing and 
combination treatments have been optimized. However, the most promising therapeutic 
advancements are agents targeting proteins encoded by genes that are mutated in malignant 
cells, such as HER-2, a member of the epidermal growth factor receptor family (EGFR).  
 
2.  Epidermal growth factor receptor family (EGFR, ErbB) 
Extracellular growth factor ligands bind to receptor tyrosine kinases (RTKs) thereby 
activating intracellular signalling pathways which result in diverse biological responses 
including cell proliferation, differentiation, cell motility and survival. The epidermal growth 
factor receptor family, which is also called ErbB (avian erythroblastosis oncogene B) family, 
represents one of the human RTKs, which is expressed, with few exceptions (e.g. 
haematopoietic cells) in cells of mesodermal and ectodermal origins [4].     
The ErbB family has four members, EGFR (HER-1 or ErbB1), ErbB2 (HER-2), ErbB3 
(HER-3), and ErbB4 (HER-4). It is regulated by various ligands, such as epidermal growth 
factor (EGF)-like proteins, transforming growth factor (TGF)-α, amphiregulin, betacellulin, 
epiregulin, heparin binding EGF-like growth factor (HB-EGF) and four known neuregulins 
(NRGs). The ErbB signalling network evolved through diversification from invertebrates. Its 
structure and function is highly conserved for more than a billion of years. In the nematode 
Caenorhabditis elegans the simplest form of the EGF receptor system is found, including one 
receptor and one ligand [5]. In the fruit fly Drosophila melanogaster one receptor already 
interacts with four ligands [6]. Finally, a complex network of 4 receptors and more than 30 
ligands is found in mammals [7]. Within this network the four cascades richly interact with 
each other and establish a layered signalling network. Evolution prefers complex networks 
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because they are trained to resist perturbation. But they are fragile to uncommon attacks, like 
recruitment of immune mechanisms by monoclonal antibodies, combination of monoclonal 
antibodies and chemotherapy or the combination of two different monoclonal antibodies 
which is currently under investigation in clinical trials [8].    
Most data on the ErbB family function in mammals derive from studies with transgenic mice. 
They showed that this signalling network plays a crucial role in cardiac and neural 
development [9-15]. The ErbB receptors also play an important role in the adult organism, 
e.g. in the postnatal differentiation of the mammary gland. HER-1 seems to function in ductal 
growth, while HER-2 and HER-4 seem to have key roles in lobulo-alveolar differentiation 
and lactation [16].   
Moreover, potent signalling pathways are activated by the ErbB receptors: Ras-MAPK, 
PI3K/Akt, PLCγ-PKC and STATs [17]. These pathways activate transcriptional programmes 
in the nucleus, e.g. proto-oncogenes fos, jun and myc, but also zinc-finger-containing 
transcription factors including Sp1 and Egr1 [4].  
In many different cancer cell types, the ErbB pathway becomes hyperactivated by different 
mechanisms: overproduction of ligands and/or receptors or constitutive activation of 
receptors.  
 
2.1 Structure of the ErbB receptors and the importance of dimerization 
All four ErbB receptors are composed of an extracellular ligand binding domain (~ 620 
residues), a single transmembrane segment (~ 23 residues), and an intracellular protein 
tyrosine kinase domain (~260 residues) that is flanked by juxtamembrane (~40 residues) and 
C-terminal (~232 residues) regulatory regions. The receptors exist as monomers and their 
activation depends on ligand binding and other receptors of the same family. Dimerization of 
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the receptors is necessary for signalling cascade activation. It can occur between two different 
ErbB receptors (heterodimerization) or between two molecules of the same receptor 
(homodimerization). 10 distinct homo-and heterodimers can be formed and are activated by 
different ligands.            
The extracellular region of the ErbB receptors is heavily glycosylated and consists of four 
domains. There are two homologous large domains (L), and two cysteine-rich domains (CR), 
which occur in the order L1-CR1-L2-CR2 [18], an alternative nomenclature is I-II-III-IV 
[19]. Ligand binding occurs on domain I and III and leads to receptor dimerization. Almost all 
receptor-receptor interactions are mediated by domain II. At the center of the dimer interface 
on domain II is a prominent loop, which has been termed the “dimerization arm”. Deletions or 
mutations in this region completely prevent ligand-induced activation [20]. EGFR, HER-3 
and HER-4 exist in a “closed” conformation in which the dimerization domains cannot 
interact with each other in the absence of a ligand (inactivated configuration). Via 
simultaneous binding to both domains, I and III, the ligand alters the orientation of these two 
domains, thereby changing the conformation of domain II, which finally result in an enhanced 
ability of the receptor to form dimers (activated configuration) [21]. Because there has not 
been found any ligand for HER-2 yet, this receptor only exists in an active “open” 
conformation and is as a consequence permanently available for dimerization [22, 23] (Figure 
1). 
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 Figure 1. The ErbB receptor family. EGFR (ErbB-1), ErbB-3 and ErbB-4 
exist in a tethered conformation, whereas ErbB-2 exist in an extended 
conformation [23]. 
 
2.2 HER-2 
The HER-2 receptor is encoded by the HER-2 gene, a proto-oncogene mapped to 
chromosome 17q21 and represents a 185kD transmembrane glycoprotein [24]. Elevated 
expression of HER-2 is found in a variety of human cancers, including mammary, bladder, 
colon, ovarian, gastric, lung and salivary gland tumours. HER-2 positive malignancies 
correlate with more aggressive tumour phenotypes including tumour size, lymph node 
involvement, high percentage of S-phase cells, aneuploidy, and lack of steroid hormone 
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receptors [25]. 20% - 30% of breast cancers overexpress the HER-2 receptor, in ductal 
carcinoma in situ even 60%. In 92% of breast cancer patients HER-2 overexpression is the 
result of HER-2 gene amplification [26]. However, overexpression can be caused additionally 
by transcriptional or post-transcriptional dysregulation [27]. HER-2 protein levels are about 
10- to 100-fold higher on the cell surface of HER-2-positive tumours compared with adjacent 
normal breast epithelial cells [28]. Elevated levels of HER-2 expression are associated with 
aggressive tumour growth and metastatic activity and thus are an indicator of poor prognosis 
[29]. In human breast cancer, HER-2 gene amplification is correlated with a shorter overall 
survival and relapse-free survival [29]. Higher levels of the extracellular domain (ECD) of 
HER-2, which can be cleaved proteolytically from the cell membrane [30] directly correlate 
with poorer prognosis and a decreased responsiveness to therapies [31].    
HER-2 has some unique properties within the ErbB family. As already mentioned it has no 
high affinity binding ligand and exists in a constitutive open conformation which suggests that 
this receptor mainly functions as a co-receptor for other ErbB receptors. Interactions between 
the receptors within the ErbB family are not random, instead, HER-2 is the preferred 
dimerization partner [32]. Heterodimerization of HER-2 enables the participation of HER-2 in 
signal transduction although a specific ligand  is missing [33]. In general, heterodimers 
generate more potent signals than homodimers. Particularly, HER-2 containing heterodimers 
show a high signalling potency, are long-lived and associated with malignant growth. 
Overexpression of HER-2 promotes the formation of more HER-2 heterodimers, particularly 
with HER-3. In contrast to HER-2 which has no ligand, HER-3 is devoid of intrinsic kinase 
activity [34]. Although, neither HER-2 nor HER-3 can support linear signalling alone, the 
heterodimer of these two is the most transforming and mitogenic receptor complex [35]. 
HER-2 forming heterodimers with HER-1 lead to a reduced degradation and an enhanced 
membrane recycling of HER-1. HER-1 homodimers normally undergo degradation in 
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lysosomes, but when heterodimerized with HER-2 it returns to the cell surface and signalling 
is prolonged  [36].  
To inhibit HER-2 mediated signalling different therapeutical approaches are currently under 
investigation. Monoclonal antibodies, such as trastuzumab and pertuzumab, lead to growth 
inhibition through different mechanisms dependent on their binding to different epitopes on 
HER-2. Combinations of antibodies and drugs, e.g. DM1, an anti-microtubuli agent, as well 
as bi-or trispecific antibodies targeting HER-2 and e.g. CD3 should enhance the efficacy of 
therapeutic antibodies. Another strategy is the application of small-molecule tyrosine kinase 
inhibitors (lapatinib), which inhibit the activation of the HER-2 tyrosine kinase domain. 
Inhibitors of heat shock protein 90 (HSP90), which normally facilitates the folding and 
conformation of proteins, lead to ubiquitination and degradation of HER-2. Another 
alternative approach would be to prevent HER-2 proteins from reaching the cell surface, by 
either blocking their transcription or their trafficking to the cell surface [4, 23]. However, to 
date the only routinely applied therapy against HER-2 overexpressing breast cancer is based 
on monoclonal antibodies. 
 
3. Monoclonal antibodies as therapeutic tools in cancer 
The vision of antibody-based therapies tracks back to the “magic bullet” concept of Paul 
Ehrlich. He postulated that selective drugs were needed which have specific affinity for 
pathogens and act as magic bullets without affecting the host’s cells [37]. The realisation of 
his vision became more feasible with the generation of the first monoclonal antibodies 
(mAbs) by Köhler and Milstein in 1975 [38]. However, the murine origin of the mAbs limited 
their clinical application because they were immunogenic when injected into humans and led 
to human anti-mouse antibody responses (HAMA). Moreover, due to their murine constant 
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antibody region, they failed to recruit human effector cells and lacked all functions of the 
immune system. The upcoming recombinant DNA technology in the early 1980s made it 
possible to generate mouse-human chimeric antibodies, with a murine variable region and a 
human constant domain which allowed the interaction with human effector cells and reduced 
the HAMA responses. Rituximab (MabThera®, Roche in EU; Rituxan®, Biogen 
Idec/Genentech in USA), a chimeric mAb, directed against CD20 on B-cells, was the first 
monoclonal antibody approved by the United States Food and Drug Administration 
(U.S.FDA) in 1997. Chimeric mAbs are 65-90% human proteins, whereas humanized mAbs 
already consist of 95% human proteins, only a few critical amino acid residues involved in the 
antigen binding are of rodent origin. The first fully human antibody, panitumumab 
(Vectibix®, Amgen), is directed against EGFR [39] and approved for the treatment of 
colorectal cancer. It is derived from transgenic mice whose immunoglobulin loci had been 
genetically inactivated and replaced with the human immunoglobulin genes [40].   
For the development of therapeutic mAbs the selection of the right target antigen is 
prerequisite. Therefore, four properties of the antigen have to be considered: (1) it must be 
characteristic for malignant cells and should not be expressed in healthy tissue, (2) it can be 
measured routinely in clinical patient samples, (3) it correlates with the clinical outcome, and 
(4) its inhibition results in a clinical response in patients positive to the target antigen [41]. 
Several tumour-associated antigens (TAA) of hematopoietic cells, including CD20, CD52 and 
CD33, receptor tyrosine kinases (HER-2, EGFR, VEGF) and other surface proteins like 
MUC-1, CEA and EpCAM have been chosen as targets for the development of mAbs. A 
monoclonal antibody directed against one of these antigens harbours two functions: i) via its 
variable domain it binds specifically to the tumour cell and ii) via the constant part it recruits 
numerous effector cells and activates complement system to function immunologically on the 
tumour cells.             
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A large number of monoclonal antibodies are currently under investigation in early or late 
stage of clinical trials. To date nine therapeutic monoclonal anti-cancer antibodies are 
approved by the FDA. They are either murine, chimeric or humanized antibodies, either 
conjugated to a radionuclide or unconjugated, but they all have in common that they are 
directed against cell surface proteins of cancer cells and are exclusively of the IgG subclass 
[42].  
 
3.1 Trastuzumab (Herceptin®) 
To generate a therapeutic monoclonal antibody the target antigen has to be chosen carefully. 
Its accessible location on the cell surface makes HER-2 an attractive target for treatment of 
HER-2 overexpressing cancers. The sequence of HER-2 was published in 1985 by Coussens 
et al [24]. When a number of different anti-HER-2 antibodies were tested, an interesting result 
was achieved: some antibodies almost completely inhibited tumour cell growth, while others 
only partially intervened. Interestingly, some antibodies even led to an enhancement of 
tumour growth [43]. The murine antibody 4D5 was finally selected for humanization because 
it had the most promising anti-tumour effects [44, 45]. As a result a humanized IgG1κ 
monoclonal antibody which was termed trastuzumab (Herceptin®) was developed by 
Genentech (South San Francisco, CA) [46].       
Clinical trials started in 1992 and finally resulted in FDA approval in 1998 for women with 
metastatic breast cancer overexpressing HER-2. In 1999, the efficacy and safety of 
trastuzumab was studied in 222 women with HER-2 overexpressing metastatic breast cancer 
that has progressed after chemotherapy. The patients received a starting dose of 4mg/kg 
intravenously, which was followed by a weekly maintenance dose of 2mg/kg. The response 
rate was 15%, the most common side effects were infusion-associated fever and/or chills and 
Chapter I 
__________________________________________________________________________________________
13 
the most clinically relevant adverse event was cardiac dysfunction in 4,7% of patients [47]. In 
a subsequent study, patients treated with chemotherapy plus trastuzumab showed a 50% 
overall response rate compared to 32% treated only with chemotherapy, a longer time to 
disease progression, a longer duration of response, a lower rate of death at 1 year, and a 20% 
reduction in the risk of death [48]. This therapeutic combination regime was also approved by 
the FDA. In the Herceptin Adjuvant (HERA) trial study the efficacy of trastuzumab in early-
stage breast cancer was analysed. Trastuzumab was given every 3 weeks for 1 or 2 years after 
adjuvant chemotherapy resulting in an absolute benefit in terms of disease-free survival at two 
years of 8.4% compared with the observation group [49].  
Trastuzumab binds HER-2 on the C-terminal portion of domain IV at the site of the binding 
pocket for the dimerization domain II.  Three loops of HER-2 are in contact with trastuzumab: 
loop 1 (residues 557-561) and loop 3 (residues 593-603) are primarily electrostatic, whereas 
loop 2 (residues 570-573) is hydrophobic [50]. Although trastuzumab belongs to the most 
well studied mAbs, is known to suppress HER-2 signalling, and is already used for passive 
immunotherapy, the exact mechanisms of its action is still not completely understood. The 
following mechanisms of action are currently under discussion [23, 51-53]: 
(1) HER-2 dimerization is prevented, although it is known that the mAb pertuzumab via 
binding to the dimerization domain II of HER-2 works more efficiently than trastuzumab. 
(2) HER-2 is endocytotically removed from the cell surface which results in degradation of 
the oncoprotein. As a consequence less HER-2 is present on the cell and less HER-2 
heterodimers can be built, thereby reducing signal transduction. 
(3) Overexpression of HER-2 on the cell surface leads to proteolytic cleavage of the receptor 
which results in the release of the extracellular domain and in the production of a truncated 
membrane-bound fragment (p95), which results in growth signals [54]. Molina et al. 
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demonstrated that trastuzumab can block the shedding of the extracellular domain of HER-2 
[55]. 
(4) Immunological mechanisms: antibody-dependent cellular cytotoxicity (ADCC) reactions 
are known to be the predominant action of trastuzumab. To perform ADCC reactions the mAb 
must bind via its Fc part to Fcγ receptors on effector cells (NK cells and monocytes). In 
genetic mouse models the involvement of the immune system in mAbs action was confirmed: 
the anti-tumour activity of 4D5 and trastuzumab was almost abolished in FcRγ-/- mice 
(lacking the stimulatory FcγRIII), while their activity was enhanced in mice lacking the 
inhibitory receptor FcγRIIb [56]. Whereas rituximab is known to mediate complement-
dependent cytotoxicity (CDC) reactions, this function of trastuzumab is controversially 
discussed. 
(5) Induction of cell cycle arrest in G0/G1 phase. Sliwkowski et al. showed that HER-2 
overexpressed cells treated with the murine 4D5 or its humanized variant result in an increase 
in the percentage of cells in G0/G1 phase [57]. 
(6) Reduction of angiogenesis by downregulation of vascular endothelial growth factor 
(VEGF) [58, 59]. 
 
4. Allergy and cancer – is allergy a risk or a protective factor in carcinogenesis? 
Today, up to 25% of the western population is allergic, which raises the question if allergic 
predisposition might have an advantage in evolution. IgE as a widespread, ancient antibody 
isotype in mammals is best-known for its unwanted reactions in allergy. However, its 
complete physiological role is not clarified in detail yet, suggesting a natural function of IgE 
in the protection against tumours. 
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Allergy and cancer are two completely different diseases increasing worldwide. Allergy 
involves IgE-mediated hypersensitivity towards harmless environmental antigens leading to 
rhinoconjunctivitis, hay fever and asthma. The symptoms can range from mild and local 
(sneezing, coughing, itching) to life-threatening systemic reactions like anaphylactic shock. In 
contrast, cancer is the consequence of uncontrolled cell growth leading to organ dysfunction 
and death. Despite these differences the biological relationship between these diseases has 
been the centre of many studies in the last decades.  
Controversial hypotheses exist trying to explain the relationship between allergy and cancer 
[60]:  
(1) Allergy has a protective effect against cancer by enhancing immune surveillance, thus 
decreasing the chance of mutated cell proliferation (immunosurveillance hypothesis). 
(2) Allergy symptoms have been evolved by natural selection to expel toxins, pathogens and 
foreign particles before they can initiate carcinogenesis (prophylaxis hypothesis). 
(3) Allergy is associated with an increased risk of cancer by inducing chronic inflammation 
and immune stimulation, which was shown in asthmatic patients with a higher risk for lung 
cancer (antigenic stimulation hypothesis). 
For years epidemiological studies try to find a correlation between the incidence of allergies 
and diverse malignancies. Controversial data vary from studies reporting a protective effect, 
to studies reporting allergy as a risk factor for cancer and others which found no correlation. 
The controversial findings may result from different study designs, restricted number of study 
participants, the failure to control important cancer risk factors, and the way how atopy is 
defined and measured which is often only based on interviews and questionnaires. The 
association between allergy and cancer is very complex and depends on the specific allergic 
and tumour disease. Most epidemiological studies are retrospective case-control studies, while 
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only the minor part are cohort studies where atopic patients are monitored over a certain time 
period. Wang et al. has reviewed epidemiological studies on this topic since 1985 and found 
mixed data, but an overall indication that allergy is associated with a reduced risk for cancer 
[61]. The biggest prospective cohort study on this topic summarized data from 1.1 million US 
men and women over a time period of 18 years. They found a significantly lowered risk of 10 
percent for overall cancer mortality and 20 percent for colorectal cancer mortality among 
persons with a history of both asthma and hay fever [62]. Despite the methodological 
problems in the epidemiological studies and the controversial results, there is experimental 
evidence that allergy might have a protective function in carcinogenesis.  
 
4.1 IgE and its effector cells 
IgE is present in serum of healthy individuals in extremely low concentrations, but is tissue 
bound in high amounts, especially in epithelia and mucosa. The function of IgE is based on 
the binding to its effector cells via two receptors: the high-affinity FcԑRI receptor (Ka= ~1010 
M-1) and the low-affinity FcԑRII or CD23 receptor (Ka= ~108 M-1). In comparison to the 
affinity of IgG antibodies for Fcγ receptors (Ka= ~106 - 108 M-1) the affinity of IgE for its 
receptors is much higher [63]. In humans, FcԑRI is expressed on mast cells, basophils, 
eosinophils, macrophages and monocytes and antigen presenting cells, e.g. dendritic cells and 
Langerhans cells, and also on platelets [64]. The serum half-life of IgE (2-3 days) is very 
short [65], but when bound in tissue the half-life of IgE is much longer (several weeks) than 
that of IgG [66].  
Receptor-bound IgE directed against a tumour-associated antigen could recruit effector cells 
to the tumour site. Binding of the IgE-effector cell complex to the tumour antigen would lead 
to cross-linking of FcԑRI and mediator release of the effector cell. Using the IgE-mediated 
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potent immune reaction and directing it specifically towards malignant cells would induce 
local inflammation at the tumour site and result in tumour regression. It is known that a high 
number of inflammatory cells can be attracted into tumours, including eosinophils, mast cells, 
lymphocytes and macrophages. Besides expressing the high-affinity IgE receptor they contain 
various substances which can either directly act in a cytotoxic or phagocytic way on tumour 
cells (IgE-mediated ADCC and ADCP) or recruit other cells detrimental for the tumour.  
Nevertheless, most anti-cancer studies have focussed on cytotoxic CD8+ T cells and natural 
killer cells. Thereupon, dendritic cells drive cytotoxic T lymphocytes (CTLs) towards tumour 
cells which expose tumour-associated antigens by their major histocompatibility complex 
(MHC) class I molecules. Sometimes tumour cells try to escape recognition by CTLs and 
downregulate MHC class I expression. TAA can also be presented by MHC class II molecules 
on CD4+ T cells by bystander antigen-presenting cells. Th2-mediated anti-tumour immunity 
can be very effective and appears to be dependent on the production of IL-4, IL-5 and the 
recruitment of eosinophils [67, 68]. 
However, tumour-associated macrophages, mast cells and eosinophils exhibit pro- and anti-
tumour effects. 
Tumour-associated macrophages (TAMs) 
Macrophages derive from monocytes which originate in the bone marrow. Monocytes have 
the potential to migrate out of the bone marrow into the blood stream. Circulating monocytes 
can leave the blood stream and enter tissue, where they differentiate into macrophages. 
Tumour-associated macrophages are a major component of tumour infiltrates having the 
potential to inhibit as well as to promote tumour growth. They secrete a number of different 
cytokines, such as interferons, interleukins and tumour necrosis factor-alpha (TNFα). 
Macrophages can execute cell killing via macrophage-mediated tumour cytotoxicity (MTC) 
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and via ADCC. MTC is antibody independent and involves the direct binding of the 
macrophage to the tumour cell, thereupon, the macrophage secrets factors such as TNFα and 
serine proteases which lead to the lysis of the target cell [69]. On the other hand, TAMs are 
able to secrete mitogenic cytokines such as platelet derived growth factor (PDGF), 
transforming growth factor-beta (TGF-β), EGF and transforming growth factor-alpha (TGF-
α), thereupon stimulating tumour cell growth and angiogenesis [69]. The presence of 
macrophages in breast cancer has been correlated with increased angiogenesis and a poorer 
prognosis [70]. 
Mast cells 
Mast cells derive from a progenitor cell in the bone marrow and migrate into the tissues where 
they mature depending on the environmental conditions. Two different types of mast cells 
have been identified: connective tissue mast cells containing tryptase and chymase (CTMC 
mast cells) and mucosal mast cells containing only tryptase (MMC mast cells). Mast cells 
have the ability to change their secretion profile according to the microenvironment and after 
stimulation they secrete preformed or de novo synthesized mediators. It is well known that 
mast cells play a central role in allergic reactions, but it became evident that they are involved 
in neuro-inflammatory, autoimmune disorders and cancer processes [71]. It has been observed 
that mast cells accumulate around the margin of cutaneous malignancies [72]. They secrete a 
lot of molecules that are either beneficial or detrimental to a tumour. FGF-2, heparin, IL-8 and 
VEGF (neovascularization), NGF, PDGF and SCF (tumour growth), histamine (tumour 
growth and immunosuppression) and proteases (tissue disruption, metastasis) are mediators 
with pro-tumour properties. On the contrary, cytokines such as IL-4 inhibits cell proliferation, 
TNF- α induces tumour cell death, heparan sulfate proteoglycans prevent neovascularisation, 
and secretion of chondroitin sulphate could stop metastasis [73, 74]. Breast cancer patients 
with mast cells in their axillary lymph nodes have a longer survival time and a better 
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prognosis [75-77]. On the other hand, the presence of mast cells around melanomas was 
correlated with increased neovascularisation, tumour aggressiveness and poor prognosis [78]. 
The group of Luiten et al. generated a murine IgE antibody, G250 IgE, binding an antigen 
presented on renal cell carcinoma. G250 IgE activated mast cells to release TNF-α and 
histamine in the presence of tumour cells [79]. In a subsequent study they developed a 
human/murine chimeric version of this IgE antibody. In experiments with a mast cell-like cell 
line, the rat basophilic leukemia (RBL) cell line, transfected with the human FcԑRI alpha 
chain (RBL-7TZ), the chimeric IgE led to activation of the RBL-7TZ, and, in a further step to 
activation of freshly isolated human basophils [80].  
Eosinophils 
Elevated numbers of eosinophils are best known for their association with allergic diseases 
and parasitic helminth infections. Eosinophils develop and mature in the bone marrow and are 
mainly found in tissues secreting a huge number of different products, including granule 
proteins (major basic protein MBP, eosinophil peroxidase EPO, eosinophil cationic protein 
ECP, eosinophil-derived neurotoxin EDN), cytokines, chemokines and oxygen metabolites 
[81, 82]. These cytotoxic granule proteins are known to induce tissue damage and 
dysfunction, a process which could be harnessed to locally destroy tumour cells [81]. On the 
other hand, they also attract fibroblasts through the release of TGF-β, FGF-2, NGF and VEGF 
and play a role in tissue repair, fibrosis and angiogenesis [82]. Eosinophils are known to be 
elevated in peripheral blood and to infiltrate the tissue in many hematologic and solid human 
tumours [83, 84]. In one of the first studies of its kind, in 1983, Pretlow et al. related the 
presence of tissue eosinophils in colon carcinoma to a prolonged survival [85] which was 
confirmed by a study in 1999 [86].          
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A study of Mattes et al. supported the positive effect of eosinophils showing that tumour 
elimination by Th2 cells in a lung metastasis model of B16-F1 CTL-resistant melanoma is 
dependent on the influx of eosinophils into the tumour site. Further, tumour clearance was 
connected with the chemokine eotaxin [68]. Another study showed that eosinophil 
accumulation occurs independently of T cell mediated immune responses and represents an 
early inflammatory reaction in carcinogenesis [87]. A recent study on this topic reported that 
eosinophils express a functional gammadelta TCR/CD3 which is involved in eosinophil 
cytotoxicity against tumour cells [88, 89]. 
 
4.2 Tumour-specific IgE for passive anti-cancer immunotherapy 
Anti-cancer immunotherapy with monoclonal antibodies is state of the art. The five Ig 
subclasses in humans differ in regard to their corresponding effector cells, receptor 
specificities and mechanism of action. IgG1 is the favoured IgG subclass for therapeutic 
applications because of its high efficacy in mediating ADCC [90]. Although they are 
successfully applied in clinical oncology, some limitations have to be considered: inadequate 
tissue distribution, limited access to tumour cells, short half-life and high costs because of 
repeated administration.           
So far, monoclonal antibodies of the IgE subclass have been neglected for clinical anti-cancer 
therapy because of their well-known unfavourable function in allergy and the risk of 
anaphylaxis. Nevertheless, IgE antibodies show a series of unique properties, which harnessed 
against a specific tumour antigen, could lead to tumour destruction [91]:  
 the speed of the immune response 
 the higher quality and amplitude of the inflammatory reaction 
 the higher affinity to receptors and its longer persistence on cells 
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 the high sensitivity of IgE-armed effector cells to antigen activation 
 the location of IgE effector cells in the tissue 
If IgE would be used for immunotherapeutic strategies the risk of any severe side reaction, 
such as anaphylaxis, has to be minimized by the appropriate choice of tumour target, the 
expression of only a single epitope on the antigen, highly specific antibodies and little 
shedding of the antigen from the tumour cells. Moreover, several studies have so far described 
that natural IgE targeting TAAs can be found in malignant lesions. None of these patients has 
experienced anaphylaxis [92].  
One of the first studies on the effects of tumour-specific IgE used a monoclonal murine IgE 
antibody recognizing an envelope glycoprotein on the mouse mammary tumour virus 
(MMTV). Passive application led to the protection of syngeneic mice against a lethal dose of 
H2712 mammary carcinoma secreting the MMTV virus. However, the mechanism behind the 
anti-tumour effect of IgE and the involved effector cells were not discussed in this study [93]. 
The biological activity of tumour-specific monoclonal IgE, mIgE 30.6, was investigated in a 
human tumour xenograft model in SCID mice. Animals were inoculated subcutaneously with 
colorectal tumour cells COLO 205 and after 5 days they received a single injection of the 
murine IgE antibody. Tumour growth and tumour size was inhibited specifically in 
comparison with a chimeric antibody recognizing the same colon cancer associated antigen, 
but consisting of a human Fc part [94]. The construction of a human monoclonal IgE antibody 
directed against the folate binding protein expressed on human ovarian carcinoma was the 
next step forward towards clinical application. Thereby MOv18-IgE was directly compared 
with its analogue MOv18-IgG. In a SCID mouse xenograft model of ovarian carcinoma the 
beneficial effect of IgE was greater and of longer duration than that of IgG. No signs of 
anaphylactic reactions were observed in any of the animals. In a subsequent study the authors 
found that human monocytes were very active in IgE-mediated ADCC. Furthermore, it was 
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speculated that the IgE could be even more efficient in human patients than in the SCID 
mouse model because human PBMC were rapidly cleared from the circulation of mice, while 
in humans the effector cells would be permanently available [91, 95].     
These studies confirm the hypothesis that IgE has the potential to trigger inflammatory and 
allergic reactions at tumour sites by the recruitment of potent tumouricidic cells. 
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Background: Mimotopes are peptides mimicking protein, carbohydrates or 
lipid epitopes and can be generated by phage display technology. When 
selected by antibodies, they represent exclusively B-cell epitopes and are 
devoid of antigen/allergen-specific T-cell epitopes. Coupled to carriers or 
presented in a multiple antigenic peptide form mimotopes achieve immu-
nogenicity and induce epitope-specific antibody responses upon vaccination. 
Objective/methods: In allergy IgG antibodies may block IgE binding to aller-
gens, whereas other IgG antibody specificities enhance this and support 
the anaphylactic reaction. In cancer, inhibitory antibody specificities prevent 
growth signals derived from overexpressed oncogenes, whereas growth-
promoting specificities enhance signalling and proliferation. Therefore, the 
mimotope concept is applicable to both fields for epitope-specific vaccination 
and analysis of conformational B-cell epitopes for the allergen/antigen. 
Results/conclusions: Mimotope technology is a relatively young theme in 
allergology and oncology. Still, proof of concept studies testing allergen and 
tumour mimotope vaccines suggest that mimotopes are ready for clinical trials.
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1.	 Introduction
In both allergy and cancer biology, antibodies may be beneficial or detrimental, 
depending on their epitope specificity  [1,2]. In allergy, specific immunotherapy 
(SIT) with allergens aims to induce antibodies which block, but do not enhance the 
allergic reaction. Similarly, in immunological targeting of antigens overexpressed 
by malignant cells, growth-inhibitory antibodies are preferred, whereas growth-
stimulating specificities should be prevented. Therefore, in both cases it is important 
to direct immune responses to inhibitory antibody epitopes of the allergen/antigen. 
Phage display technology enables the selection of mimotopes that structurally 
mimic such B-cell epitopes. These mimotopes can be used to localize conformational 
epitopes and, more importantly, for active immunization strategies. The induced 
antibodies directed against the native allergen/antigen represent a polyclonal 
humoral immune response with memory function. Thus, mimotope technology 
opens new avenues for epitope-specific treatment of allergy and cancer.
2.	 Current	status	of	allergy	treatment
Today, an average of 23% of the population in industrialized countries suffers 
from seasonal allergic rhinitis  [3]. Thereby IgE antibodies, elicited against harmless 
antigens, cause mild to severe symptoms and even life-threatening anaphylactic 
reactions. Current clinical strategies for the prevention of allergic symptoms 
involve allergen avoidance by patients, pharmacotherapy or SIT. In 1911 Noon 
and Freeman reported for the first time, to our knowledge, the efficacy of immu-
notherapy for the treatment of type I hypersensitivity  [4]. For almost a century the 
principle of therapy has not changed much and is routinely applied against airborne 
1.  Introduction
2.  Current status of allergy  
treatment
3.  Current status of cancer  
treatment
4.  Phage display technology
5.  Utilizing mimotopes to localize 
epitopes by computer modeling
6.  Making the mimotope  
immunogenic
7.  Epitope-specific vaccination 
with mimotopes
8.  Conclusion
9.  Expert opinion
Chapter I 
________________________________________________________________________________________________________
37 
Mimotope	vaccination	–	from	allergy	to	cancer
494	 Expert	Opin.	Biol.	Ther.	(2009) 9(4)
allergens  and hymenoptera venom  [7]. The treatment, 
accepted by the WHO, comprises repeated administration 
of increasing doses of allergen extracts to actively induce 
tolerance towards allergens in patients suffering from rhi-
noconjunctivitis and asthma  [5,6][8]. The efficacy of SIT is 
clinically well-documented, but the molecular background 
including humoral and cellular mechanisms, is to date 
incompletely understood  [9].
During treatment an increase of allergen-specific IgG 
antibodies  [10], particularly IgG4 and IgG1 isotypes  [11], is 
observed, sometimes accompanied by a decrease of allergen-
specific IgE serum levels. Later it was shown that the increase 
of allergen-specific IgG antibody levels towards the individ-
ual allergens in an extract and the alteration of specific IgE 
do not necessarily correlate with the outcome of therapy  [12]. 
Furthermore, the exact determination of allergen-specific 
IgG is even complicated by the presence of anti-IgE autoan-
tibodies  [13]. Wachholz et al. reported that IgG antibodies 
induced by grass pollen immunotherapy were able to block the 
IgE-facilitated antigen uptake by B-cells and subsequently 
the presentation of allergens to T-cells  [14]. This refers to the 
fact that, beside the humoral anti-allergen response, allergen-
specific T-cells also play an important role in allergic inflam-
mation. In contrast to conformational epitopes of B-cells, 
T-helper cells recognize short linear fragments of allergens which 
are presented by HLA class II molecules on antigen presenting 
cells (APCs). In sensitized healthy individuals, regulatory T (Treg) 
cells are the dominant subset specific for allergens, whereas 
patients with allergy show a bias towards allergen-specific 
T helper type 2 (TH2) cells. The induction of a tolerant state 
in peripheral T-cells represents an essential step in SIT  [15]. On 
the cellular level the induction of IL-10-producing Treg cells  [16], 
and the shifting from a TH2 to a TH1 cytokine profile  [17] 
are known to contribute to a successful immunotherapy.
SIT harbours a certain risk for side effects, such as the 
possibility of large local inflammatory  [18] and anaphylactic 
reactions  [19]. Allergen extracts used for SIT are prepared 
from natural allergen sources and show high variation in their 
protein composition and amounts. They consist of allergenic 
and nonallergenic components  [20,21], therefore they cannot be 
adjusted precisely to the patient’s profile. Subsequent induction 
of new sensitization to irrelevant components has been 
observed after this treatment. Thereby, IgE antibodies are 
produced de novo against previously unrecognized B-cell epitopes 
on the allergen  [22-24]. To make SIT more safe several attempts 
have concentrated on the concept of component-resolved diagno-
sis and therapy, which is based on recombinant allergens and 
hypoallergenic allergen derivatives. The advantage of recom-
binant allergens is the production of molecules with defined 
quality devoid of irrelevant components, allowing treatment 
according to the patient’s sensitization profile  [25]. Neverthe-
less, recombinant allergens still may present novel epitopes 
that possibly elicit new IgE antibody specificities. To bypass 
this unwanted reaction other studies focus on the concept of 
epitope-specific immunotherapy.
2.1	 The	importance	of	epitope	specificity	in	allergy
The blocking capability of IgG is due to an antigen trapping 
or due to a blockade of the IgE-facilitated allergen presentation 
by B-cells to T-cells [14,26]. Furthermore, co-crosslinking of 
FcεRI and FcγRIIb receptors by allergen-IgG complexes can 
negatively regulate allergy effector cells [27]. To be able to 
compete with IgE being a high affinity antibody, one would 
expect that high affinity of the IgG to the allergen repre-
sents a desirable feature of a potential blocking antibody. In 
surface plasmon resonance studies, however, none of the 
tested purified human or murine monoclonal IgG antibod-
ies were able to reach the affinity of IgE antibodies to aller-
gens [28]. Moreover, an affinity maturated anti-allergen IgG 
antibody recognizing the wrong epitope will, even though 
present in molar excess, not successfully interfere with the 
binding of IgE to the allergen [29]. It was demonstrated that 
among different monoclonal antibodies specific for birch 
pollen major allergen Bet v 1 some antibodies were able to 
block IgE binding to Bet v 1, whereas others were able to 
even promote IgE recognition of Bet v 1 [30] in vitro [1] and 
in vivo [31]. The mechanism might be linked to the promo-
tion of homodimerization and thus the IgE crosslinking 
capability of allergens [32] (Figure 1).
Consequently, SIT with whole allergen extracts or recombi-
nant proteins, respectively, will produce both types of 
anti-allergen IgG, anaphylactogenic and blocking antibodies.
Therefore, it is crucial to systematically analyse the structural 
details of IgE epitopes on allergens. In principle, epitopes 
can be either of the linear (continuous) type, or of a con-
formational nature. Conformational, discontinuous epitopes 
are formed when amino acid residues that are not 
neighbouring within the sequence become spatially juxta-
posed in the folded protein. For several allergens it could be 
demonstrated that effective IgE binding depends on their 
three-dimensional structural integrity  [33]. In contrast, linear 
epitopes are formed by adjacent amino acid residues and 
may be inaccessible in the native conformation. A number 
of studies have tried to delineate B-cell epitopes from the 
primary amino acid sequence of proteins. This strategy is 
limited to the identification of solely linear epitopes, whereas 
B-cell epitopes cannot be predicted from these analyses 
because of their conformational nature  [34]. Epitope-mimics, 
so-called mimotopes, represent a close approximation of the 
original 3D-epitope, even though their amino acid composi-
tion rarely shows similarities. This is due to the fact that mimo-
topes mimic an epitope by their biochemical and electrostatic 
properties, and not necessarily by sequence homology  [35]. 
With the phage display technology it is possible to generate 
such structural mimics of B-cell epitopes.
3.	 Current	status	of	cancer	treatment
Whereas active immunotherapy is the preferred option in allergy 
treatment today, in cancer therapy passive immunotherapy 
is state of the art. Advances in recombinant DNA technology 
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enabled the development of chimeric and humanized mono-
clonal antibodies that are far less antigenic than the original 
mouse monoclonal antibodies and exhibit longer half-lives 
within the serum  [36]. With this invention a new area of 
anti-cancer therapy based on monoclonal antibodies addi-
tional to the classical treatments of cancer including surgery, 
radiation and chemotherapy began. Targets for monoclonal 
antibodies are growth factor receptors and surface protein and 
non-protein antigens overexpressed on malignant cells. 
Furthermore, antibodies have been armed with cytokines, 
chemotherapeutic agents, toxins, and radionuclides to aug-
ment their tumouricidic efficacy  [37]. In 1997, rituximab 
(MabThera®, Roche in EU; Rituxan®, Biogen Idec/
Genentech in USA) directed against CD20 on B-cells for 
the treatment of non-Hodgkin’s lymphoma, became the first 
approved monoclonal antibody; since then nine monoclonal 
antibodies have received approval from the United States 
(FDA) to date for anti-cancer therapy, all of them of the 
IgG class  [38,39].
One of the clinically most used monoclonal antibodies, 
trastuzumab (Herceptin®, Roche), is directed against the 
extracellular domain of human epidermal growth factor 
receptor 2 (HER-2)  [40,41], a member of the EGFR family. 
HER-2 constitutively exists in an activated conformation  [42], 
lacks ligand-binding activity and its signalling depends on 
heterodimerization with other members of the EGFR 
family, preferentially with HER-3  [43,44]. Trastuzumab was 
originally selected from a series of monoclonal antibodies, 
among which were detrimental, growth-promoting species. 
Trastuzumab acts via mediating antibody-dependent cellular 
cytotoxicity (ADCC), blocking the shedding of the extracel-
lular domain of HER-2, reducing HER-2 signalling by 
physically inhibiting homo- or heterodimerization, initiation 
of G1 arrest and inhibition of angiogenesis  [45,46].
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Figure	1.	The	effects	of	IgG	in	allergy	and	cancer. Depending on their epitope specificity IgG antibodies can either inhibit or promote 
allergic reactions or tumour growth. A. In allergy, specific IgGs enhance the IgE binding to allergens and the anaphylactic reaction, 
which could be due to supporting the crosslinking capability of allergens. B. On the one hand, inhibitory IgG antibodies which recognize 
the IgE epitope on the allergen directly block the binding of IgE to the allergen, thus, preventing mediator release. On the other hand, 
IgGs can act via the FcγRIIb receptor: On B-cells this results in an inhibition of IgE-facilitated antigen presentation. The inhibitory effect 
on FcεRI positive effector cells is not illustrated. C. In cancer, heterodimerization of HER-2, HER-3 and other family members leads to 
signalling and proliferation. Therefore, antibodies promoting heterodimerization are detrimental. D. In contrast, IgG antibodies hindering 
heterodimerization prevent signal transduction and cell growth.
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Generally, high costs, repeated administration to achieve 
sufficient antibody titres and anti-tumour activity, as well as 
inadequate tissue distribution in the patients are the limiting 
factors in passive immunotherapy. An alternative, more 
patient-friendly approach is active immunotherapy with 
mimotopes, producing a polyclonal immune response consisting 
of the desired antibody specificity and additionally stimulating 
immunologic memory.
3.1	 The	importance	of	epitope	specificity	in	cancer
From the above it is clear that epitope specificity plays a 
crucial role in the development of immunotherapy with 
monoclonal antibodies. To focus on trastuzumab, one has to 
mention that originally a number of anti-HER-2 antibodies 
had been isolated  [47]. Among them, 4D5 (later trastuzumab) 
was selected due to its growth-inhibitory functions  [48], in 
contrast to others, which even stimulated cancer cell 
growth  [49]. The difference in their biological activity is 
strictly dependent on the respective targeted epitope on 
HER-2 and has to do with their ability to hinder or promote 
heterodimerization of HER-2, the latter inducing signal 
transduction and cell proliferation  [2] (Figure 1). For this 
reason the characterization of tumour antigen epitopes is a 
basic step in developing epitope-specific immunotherapy. 
Yip et al. identified large and conformational B-cell epitopes 
on the tumour antigen HER-2  [2]. In 2003 Cho et al. 
successfully defined the binding site of trastuzumab as an 
epitope composed of three loops on the HER-2 mole-
cule  [50]. The work by Riemer et al.  [51] showed that it is 
feasible to imitate such complex epitopes using peptide mimics 
generated by phage display technology: five characterized 
HER-2 mimotopes indeed matched to loop three, as defined 
by Cho et al.
4.	 Phage	display	technology
Phage display technology, first introduced by G. Smith in 
1985  [52], is an advanced tool to define peptide structures 
that mimic natural epitopes including both conformational 
and linear epitopes. These peptides are called mimotopes  [53]. 
The strength of the phage technology lies in the display of 
up to 109 different peptides in a library form enabling the 
selection of mimotopes in a repetitive screening procedure. 
A large number of protein–antibody, virus–antibody and 
ligand–receptor interfaces have already been mapped by the 
use of phage display technology  [54].
For the creation of a peptide phage display library random 
oligonucleotides are inserted into the genome of the filamentous 
bacteriophage fd using either the minor coat protein pIII 
(display of 3 – 5 copies/phage)  [52] or the major coat protein 
pVIII (display of up to 2700 copies/phage)  [55] as display 
system on the surface of the phages. The peptides can be 
presented in either linear or circular form. To construct circu-
lar peptides the sequence has to be flanked by two cysteine 
residues. By building a disulfide bond a constrained cycle is 
formed and presented on the phage surface  [56]. Beside the 
different structural presentations, the length of the peptides 
can vary from 6 to 38 amino acids  [57]. Thus, within this 
phage system only the presentation of relatively short pep-
tide sequences is possible, whereas larger gene insertions of 
proteins or antibody fragments appear to prevent pIII and 
pVIII functions necessary for phage reproduction  [57]. To 
overcome this problem phagemid systems have been devel-
oped  [58]. The phagemid itself carries only the phage gene 
gIII or gVIII, containing the foreign sequence, and needs a 
helper phage with all the necessary genes for phage produc-
tion including also a copy of the wild-type gene used for 
display. Therefore, both recombinant and wild type proteins 
will be produced and incorporated into the phage particle. 
For pIII one of five copies, and for pVIII from 1% to 30% 
of the 2700 copies will display the foreign protein  [59]. For 
the production of combinatorial antibody libraries primarily 
phagemid systems are used resulting in the display of 
‘giant mimotopes’, most often in association with pIII. 
Antibody display can be performed: i) by antibody fragment 
(Fab) systems, including two light chain domains (variable 
and constant) and the variable and first constant domain of 
the heavy chain; ii) by single-chain variable fragment (scFv) 
systems where only the variable domains of each chain are 
presented; or iii) by single-chain Fab (scFab)  [59].
4.1	 Biopanning-selection	and	characterization	of	the	
mimotope
In ‘biopanning’  [60] allergen- or antigen-specific antibodies 
of interest, monoclonal or polyclonal, are adsorbed on 
microtiter plates and incubated with a phage display library 
containing the complete repertoire of the respective library. 
Phages displaying peptide or protein domains which bind to 
the antibodies are caught whereas unbound phages are 
removed by washing steps. Bound phages are then eluted 
from the complexes by acidic solutions (such as HCl or gly-
cine buffer) or by competition with the original antigen, if 
available. Amplified phage particles of the preceding round 
are used as starting material for the next panning round. 
Thereby, specifically interacting ligands can be amplified 
with great efficacy. Eluents from the biopanning rounds are 
tested by ELISA or other immunological methods. An 
increase in the titre of phage particles specifically binding to 
the selection antibody during the panning rounds is a first 
indicator of successful selection. Subsequently, the colony 
screening method is used to identify specifically interacting 
phage clones for further analysis. Generally, a strong signal 
in these tests predicts good mimicry of the original antigen, 
but this has to be additionally proven by competition assays 
with the original antigen or allergen  [61]. After sequencing 
the most promising clones, computational matching studies 
can be performed using a software program rendering visual-
ization of the location and the structural features of the 
epitope of interest  [51,62]. Subsequent immunization studies 
with the mimotopes must prove molecular mimicry and 
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should lead to antibodies recognizing the original allergen/
antigen. Figure 2 illustrates the principle of mimotope selec-
tion, starting from the choice of the antibody used for bio-
panning to the desired allergen/antigen-specific immune 
response in mice.
5.	 Utilizing	mimotopes	to	localize	epitopes	by	
computer	modeling
Several groups have invented algorithms and programs that 
assist epitope mapping. They work with mimotope and antigen 
sequence information  [63], or with mimotope sequence and 
antigen structure  [64-66], or integrating the different approaches. 
A recent publication presents the Pep-3D-Search approach for 
predicting the epitope area through mimotopes or a motif 
sequence derived from a set of mimotopes  [67]. Among all, 
MIMOX was the first free web tool for structural mapping 
of an antibody epitope by mimotope information  [68].
During our own early work with mimotopes these programs 
were not available and we were forced to develop different 
methods to approach the question of 3D-epitope mapping: 
i) In an attempt to characterize a structural IgE epitope on 
birch pollen allergen Bet v 1, a computer-aided, 3-dimensional 
coarse-grained epitope search was developed  [69]; ii) More 
recently, when we characterized the IgE epitopes of house 
dust mite allergens Der p 1 and Der p 2  [62] epitope match-
ing was performed using BALL (Biochemical Algorithms 
Library)  [70]. Two criteria were used to assess the quality of 
the potential epitope: solvent exposure and amino acid simi-
larity assessed by a modified Gonnet matrix  [71]; and iii) Even 
more challenging was the alignment of mimotopes to HER-2 
due to the 10 times larger molecular size than with allergen 
molecules resulting in the need for higher calculation power. 
Based on the antigen molecule’s spatial structure from the 
RCSB Protein Data Bank  [72] the algorithm took into 
account the relative flexibility of short peptides when scan-
ning a given protein surface for matching sites  [51]. Further, 
for investigations of mimotope–antibody interactions we took 
advantage of AutoDock 3.0.5  [73]. With this program it is 
possible to dock the oligopeptides to the Fab fragment of 
interest  [35]. Taken together, the computational approaches 
available today allow allocation of B-cell epitopes with a 
high predictive accuracy.
6.	 Making	the	mimotope	immunogenic
After mimotope characterization the obtained information 
must be applied to design an immunogen for successful 
induction of an epitope-specific immune response. Peptides 
are too small to elicit an immune response and are, therefore, 
immunologically ignored  [74] or may induce tolerance  [75]. 
Phage particles themselves are highly immunogenic because 
they carry sufficient T-helper cell epitopes on their sur-
face  [76]. On the other hand, phage-displayed mimotopes are 
not suitable for clinical studies in humans because the phage 
particles carry foreign DNA and antibiotic resistances. 
Therefore, alternative carrier systems have to be chosen 
which are necessary for achieving sufficient immunogenicity 
for vaccination.
Keyhole limpet hemocyanin (KLH) is a large protein that 
acts as a carrier, causes a strong immune response and provides 
additional T-helper cell epitopes, which is important as 
T-helper cells B-cells stimulate to increase their production 
level and quality of antibodies  [77]. In parallel, also cytotoxic 
T-lymphocytes (CTLs) may be activated through T-helper-
cell-derived IL-2. Tetanus toxoid (TT) represents a carrier 
protein similar to KLH with T-helper activity and has also 
been used as a peptide carrier previously  [78,79]. In order to 
prevent crosslinking of preexisting IgE in allergy, the choice 
of the appropriate carrier system of an allergen mimotope 
has to be taken into consideration when constructing a vaccine. 
In an allergology study albumin binding protein (ABP) was 
used to construct a monovalent fusion protein with a mimotope 
of the birch pollen allergen Bet v 1  [80].
Another option to present a mimotope in a way suitable 
for immunization is the multiple antigenic peptide system 
(MAP), where linear peptides are synthesized in a straight-
forward manner on a tyrosine backbone allowing a dense 
display of the peptides  [81]. Recently, we synthesized a linear 
mimotope for the carcinoembryonic antigen (CEA) in MAP 
form and termed it “multiple antigenic mimotope” (MAM). 
This CEA–MAM was used for successful anti-cancer vacci-
nation in a murine tumour transplant model  [82]. Generally, 
for the vaccination with mimotopes one has to consider that 
the orientation and the structure of the mimotope in the 
vaccine should be the same as it was when displayed on the 
phage during biopanning. Table 1 summarizes the advantages 
and disadvantages of mimotope vaccination.
7.	 Epitope-specific	vaccination	with	mimotopes
7.1	 Mimotopes	in	allergy
Phage display technology was first applied in allergology to 
isolate a mimotope of the plant panallergen profilin by 
performing a biopanning experiment with purified IgG/IgE 
antibodies from the serum of profilin allergic patients. 
Constrained and linear random nonapeptide libraries were 
screened with the anti-profilin antibodies. The selected mimo-
tope represented a cross-reacting epitope mimic for IgE anti-
bodies directed against mugwort, birch pollen and celery tuber 
profilin and it was concluded that therapies with such peptides 
might block the antigen binding sites of IgE without cross-
linking and subsequent mediator release  [83]. Consecutively, 
a similar panning experiment was performed with two murine 
monoclonal IgG antibodies, BIP1 and BIP4, directed against 
the major birch pollen allergen Bet v 1  [84], and with purified 
IgE from birch-pollen-allergic patients. As expected, alignments 
with the Bet v 1 amino acid sequence showed no linear 
homologies, but the epitopes could be localized by a computer-
aided mathematical approach based on three-dimensional 
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structure and chemical character of the amino acids  [69]. 
Immunization with IgE mimotopes coupled to ABP in a 
monovalent fashion did not elicit type I skin reactions and, 
furthermore, induced allergen-specific IgGs that were able to 
inhibit IgE binding to Bet v 1  [80]. Again indicating the 
importance of epitope specificity, immunization with the 
BIP1 mimotope yielded anaphylactogenic antibodies  [31].
Besides Bet v 1, which is recognized by 95% of birch pollen 
allergic patients, Phl p 5, the major grass pollen allergen, 
represents another important target for immunotherapy 
in allergy. Using Phl p 5a-specific IgE antibodies purified 
from allergic patients and screening a peptide as well as a 
combinatorial Fab library, conformational IgE epitopes could 
be identified with the help of the selected mimotopes. Fur-
ther, Fabs and peptide mimotopes induced anti-Phl p 
5a-specific immune responses in mice  [85,86], even when 
injected in a DNA minigene format  [87].
Furthermore, B-cell epitopes were successfully defined for 
parvalbumin, the major fish allergen  [88] and for the two major 
house dust mite allergens, Der p 1 and Der p 2  [62]. The latter 
confirmed a previous study defining a Der p 1 epitope by a 
biopanning approach with a non-constrained 15mer- and a 
constrained 9mer-peptide library  [89]. The selected Der p 1 and 
Der p 2 mimotopes determined epitopes within the conserved 
Immunization
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Figure	2.	The	principle	of	mimotopes. The first step in generating mimotopes is the choice of an antibody recognizing the allergen/
antigen of interest. In allergy, biopanning can be carried out with allergen-specific IgE whereas in cancer, an inhibitory monoclonal 
antibody against the tumour antigen of interest is chosen. During biopanning mimotopes are selected and further investigated for 
specificity to the original antibody. Afterwards, mimotopes are tested for their ability to compete with the native allergen/antigen for 
binding to the original antibody. The selected mimotope is coupled to a carrier and used for immunization studies. After successful 
immunization, mice produce antibodies against the same epitope of the original allergen/antigen which is recognized by the antibody 
used for biopanning.
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regions of the allergens. As crossreactive allergens not only share 
similar amino acid sequences but also structural homology, the 
generation of such mimotopes could be useful for the development 
of SIT targeting epitopes within a clinically cross-reactive allergen 
group  [62]. A recent study identified two relevant conforma-
tional IgE-binding regions of Pru p 3, the major peach allergen, 
using a 12mer-random peptide phage display library  [90].
The role of T-cell help for the formation of allergen-specific 
antibodies after immunization with phage-displayed mimotopes 
was investigated in proliferation studies with murine spleno-
cytes. As expected, it was shown that the 11mer-mimotope 
did not crossreact with the allergen at the T-cellular level. It 
is tempting to speculate that this might be an ultimate 
advantage, as allergen-specific T-lymphocytes, which nourish 
chronic allergic inflammation  [91] cannot be activated by the 
applied mimotopes. However, phage-displayed mimotopes 
were able to drive spleen cells to proliferation indicating that 
the carrier contributes to the immune response in a mimo-
tope vaccine by recruiting bystander T-cells that help B-cells 
to generate an appropriate humoral immune response  [92].
7.2	 Mimotopes	in	cancer
Much more than in allergy, mimotope work has accelerated 
in cancer research since the first application of this technology 
in 2000: one group screened a phage display library with 
the mouse monoclonal antibody BCD-F9, which recognizes 
an unknown antigen found on the surface of many tumour 
cells. After four rounds of biopanning they selected one 
linear decapeptide, which was able to inhibit the binding of 
BCD-F9 to HT-1080 fibrosarcoma cells. Moreover, the poly-
clonal antibodies generated by immunization of rabbits 
bound specifically to HT-1080. Importantly, in a tumour 
metastasis model with CD-1 nude mice, passively applied 
anti-mimotope sera led to a prolonged life span  [93].
Table	1.	Advantages	and	disadvantages	of	mimotope	
vaccination	in	allergy	and	cancer.
Advantages	of	mimotopes
Easily obtained by the phage display technology
High stability in storage
Cheaper than the production of monoclonal antibodies
Free of contamination with toxic substances (e.g., from 
expression systems)
Coupling to immunogenic carrier molecules enhancing their 
antigenicity
Induction of an epitope-specific humoral immune response
Do not contain allergen/antigen T-cell epitopes
Induction of a long-lasting immune response/ no turn off
Disadvantages	of	mimotopes
Induction of a long-lasting immune response/ no turn off
Lower affinity than original antibody
7.2.1 Tumour-associated carbohydrate antigens (TACAs)
Carbohydrates are primarily T-cell independent antigens that 
elicit low antibody responses and poor memory. The immuno-
genicity of these antigens has to be enhanced either by coupling 
to an appropriate carrier or by turning the carbohydrate into 
a peptide structure mimicking the original antigen. Mimotopes 
for different carbohydrate antigens such as GD3/GD2, 
Lewis Y and sialyl-Lewis X have been developed  [94]. GD2, 
a disialoganglioside, is a relevant tumour antigen expressed 
on various tumours including neuroblastomas. Using the 
chimeric anti-GD2 antibody 14.18, which is applied for 
diagnostic purposes and had already entered clinical trials  [95], 
a biopanning screening was performed. The selected circular 
mimotopes were analysed in a computer modelling program 
and fit well into the GD2 binding groove of an anti-GD2 
Fab antibody  [35]. In the subsequent study these mimotopes 
were coupled to KLH and administrated as active immuno-
therapy in mice, inducing a GD2-specific humoral immune 
response  [96]. These and other GD2 mimotopes have been 
successfully used for immunization in DNA form  [97,98]. 
The DNA-vaccine-induced antibodies recognized GD2-positive 
tumour cells, mediated complement-dependent cytotoxicity 
(CDC) and exhibited a reduction of GD2-positive melanoma 
growth in SCID mice after passive administration  [98].
7.2.2 HMW-MAA and Mel-CAM in melanoma
In melanoma, the human high-molecular-weight melanoma-
associated antigen (HMW-MAA)  [99-101] and the melanoma 
cell-adhesion molecule (Mel-CAM)  [102] have been used for 
mimotope vaccination studies.
In parallel studies the anti-HMW-MAA monoclonal 
antibody 225.28S which is known to suppress the metastatic 
potential of melanoma cells  [103,104] was used for mimotope 
selection in biopanning experiments. We generated a 
mimotope-fusion protein with ABP and immunized 
BALB/c mice [100], whereas the group of Wagner et al.  [99] 
performed immunization studies in rabbits administrating 
mimotopes coupled to TT. Independently, both groups 
showed a specific anti-HMW-MAA anti-body response 
blotted and on the surface of intact melanoma cells. Even 
more important, the elicited antibodies inhibited the in vitro 
growth of melanoma cells and exhibited ADCC potential. 
Both studies demonstrated the principal potential of a 
mimotope vaccine in melanoma. In 2008, Wagner et al. 
published a study where they purified anti-HMW-MAA 
antibodies in rabbits after mimotope immunization and 
tested them in vivo in a SCID mouse melanoma xenograft 
model. A prophylactic and a therapeutic approach revealed that 
tumour growth was inhibited significantly  [105].
Monoclonal antibody MAd18-5D7 against the melanoma 
antigen Mel-CAM was used for generation of mimotopes 
using a 28mer-peptide library. The authors showed that the 
28mer- mimotope peptides alone were sufficiently antigenic 
to elicit a specific IgG response against Mel-CAM, but at 
lower titres than obtained with peptides linked to TT as a 
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carrier. They further observed the production of TH1-type 
cytokines from mimotope-stimulated proliferating spleen 
cells  [102]. This may be due to mimotopes acting themselves 
as T-cell epitopes after antigen processing and presentation.
7.2.3 Growth factor receptors
Numerous studies in cancer have concentrated on the epidermal 
growth factor receptor family including four members, 
HER-1 (EGFR, ErbB1), HER-2 (ErbB2), HER-3 (ErbB3) 
and HER-4 (ErbB4), which are important for regulation of 
cell proliferation and differentiation  [106]. Early studies using 
phage display methodology with three different tumour 
inhibitory anti-HER-2 antibodies indicated that due to the 
absence of sequence homology the epitope was most probably 
of conformational nature  [107]. Our group has focused on 
the production of mimotopes for EGFR and HER-2 and, 
performed biopannings with the monoclonal antibodies 
cetuximab (Erbitux®, MerckKGaA) and trastuzumab  [108,109]. 
Both antibodies are currently applied for passive immunother-
apy: cetuximab is approved for therapy in EGFR-overexpressing 
advanced colorectal cancer and trastuzumab for the treatment 
of patients with metastatic breast cancer overexpressing 
HER-2  [38]. In both cases, the mimotope-induced antibodies 
mediated ADCC and CDC reactions, receptor internaliza-
tion from the cell surface and a dose-dependent inhibition 
of tumour cell proliferation in highly specific manner and at 
a similar intensity to the original antibodies  [108,109].
Besides the biopanning approach various groups have defined 
peptide mimics of tumour B-cell epitopes via computer-aided 
analysis. Dakappagari et al. designed in silico B-cell epitope 
peptides of HER-2, facilitated their folding mimicking the 
native protein structure and synthesized them collinearly 
with a promiscuous T-helper cell epitope derived from the 
measles virus fusion protein. Active immunization with one 
of these peptide constructs prevented the development of 
tumours in mice transgenic for the rat neu gene  [110]. Alterna-
tively, they combined two HER-2 B-cell epitope constructs, 
applied this multi-epitope vaccine in combination with 
IL-12 as a TH1 adjuvant and observed a significant reduction 
in the number of HER-2 positive lung metastases  [111].
Another group also generated HER-2 peptides representing 
B-cell epitopes of HER-2, which specifically induced anti-
HER-2 antibodies able to mediate ADCC reactions  [112]. 
This multi-peptide vaccine coupled to TT significantly 
delayed tumour formation and progression in vivo in FVB/N 
mice carrying the activated rat c-neu oncogene, under the 
control of a mouse mammary tumour virus promoter 
(MMTV-c-neu mice), which develop spontaneous breast 
tumours. Furthermore, the co-administration of IL-12 led 
to elevated IFN-γ levels and an increase in IgG2a antibody 
titre supporting the anti-tumour activity  [113].
7.2.4 CD20
Another interesting tumour target is CD20 which is expressed 
on all mature B-cells, but not on their progenitor cells. 
Therefore, monoclonal antibodies to this antigen will destroy 
both benign and malign mature B-cells, but allow the 
progenitor cells to re-establish normal hematopoietic cell 
lines  [114]. Li et al. have generated mimotopes of CD20 
using rituximab in a biopanning approach. They screened a 
12mer peptide library and coupled the best mimotope with 
respect to mimicry potential, to KLH and TT for immuni-
zation experiments in BALB/c mice. With immunofluorescence 
staining and flow cytometry assays they showed that the 
immunized mice produced antibodies recognizing the native 
CD20 protein on tumour cell surfaces. Furthermore, in a 
CDC assay they proved the biological activity of the induced 
rituximab-like antibodies. None of the peptides showed 
sequence homology to CD20 in database alignments confirming 
that conformational epitopes play an important role also in 
this type of anti-cancer therapy  [115].
7.2.5 CEACAM-5
Carcinoembryonic antigen-related cell adhesion molecule 5 
(CEACAM-5) is a poorly immunogenic glycoprotein and an 
important tumour marker, especially for colorectal cancer. It 
is expressed at up to 100 times higher levels in malignant 
tumour tissue samples compared with healthy tissues. 
A biopanning performed with the monoclonal anti-CEA 
antibody Col-1 led to the generation of a CEA mimotope 
which was synthesized as an octameric MAM and further 
studied in a mouse model. When BALB/c mice were pro-
phylactically immunized with the MAM before subcutane-
ously receiving transplants of a tumour cell line overexpressing 
CEA, Meth-A/CEA, a specific and significant inhibition of 
tumour growth could be observed  [82].
7.3	 Mimotopes	in	allergooncology
The assumption on an inverse association between allergy 
and IgE levels and cancer derives from epidemiological data. 
Among other reports, a cohort study of 1,102,247 US men 
and women suggested a significant inverse association between 
a history of hay fever, and asthma and cancer mortality  [116]. 
Engineered anti-tumour IgE antibodies have a high cytotoxic 
capacity due to interaction with potent effector cells. 
However, natural IgE has also been described in squamous 
cell carcinoma of the head and neck  [117] and in pancreatic 
cancer where its cytotoxic potential was demonstrated 
also  [118]. The mechanisms of anti-tumour IgEs have already 
been studied in detail in several previous experiments  [119-121], 
among them ADCC and antibody-dependent cell-mediated 
phagocytosis (ADCP)  [122] seem to be most important. The 
IgE subclass has several advantages compared with IgG: it is 
bound with high affinity to receptors on its effector cells, 
the half-life of IgE in the periphery is longer than that of 
IgG and the effector cells expressing IgE receptors have been 
described within and around the tumour tissue  [123]. 
Therefore, IgE antibodies directed against a tumour-associated 
antigen (TAA) could specifically trigger an immediate local 
effector cell response against the tumour cells  [122]. 
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Consequently, also the threat of systemic anaphylaxis has to be 
taken into consideration. However, in the presence of natural 
anti-tumour IgE antibodies (see above) no anaphylactic events 
were observed. This may be due to the fact that circulating 
TAAs which were shed from the tumour cell membrane are 
monovalent and thus not able to crosslink cell bound IgE. 
In contrast, overexpressed TAAs on the tumour membrane 
can crosslink IgE and release tumouricidic mediators from 
effector cells exactly at the site where they are needed.
To establish an active vaccination for the directed induction 
of tumour-specific IgE antibodies the above mentioned HER-2 
mimotope  [108] was applied orally in connection with anti-
ulcer medication. The rational for this derives from the 
observation that IgE antibodies are preferentially induced 
when peptic digestion is hindered under anti-acidic treat-
ment  [124]. As expected, BALB/c mice immunized with the 
HER-2 mimotope via the oral route under anti-acidic treat-
ment developed IgE antibodies cross-reactive with the original 
antigen HER-2. Moreover, the HER-2-overexpressing breast 
cancer cell line SKBR-3 specifically crosslinked the induced 
IgE in a rat basophilic leukemia (RBL) assay. Furthermore, 
the released mediators, potentially through TNF-α action  [125], 
acted tumouricidal on SKBR-3 cells. The effect was highly 
specific, as with a HER-2-negative control cell line no cyto-
toxicity was observed  [126]. Thus, depending on the route 
and adjuvant, mimotopes may be used for a directed induction 
of anti-tumour IgE antibodies.
8.	 Conclusion
Epitope specificity can of decisive importance in the devel-
opment of vaccines, which are primarily based on a humoral 
immune response. In the fields of allergy and cancer, it has 
been demonstrated by preclinical studies that epitope mimics 
can be used to define B-cell epitopes on allergens/antigens 
of interest and, more importantly, upon immunization 
actively induce epitope-specific antibodies. The elicited antibodies 
can block the allergen–IgE interaction. Moreover, as the mimotopes 
do not contain allergen-specific T-cell epitopes, reactivation 
of inflammatory allergen-specific T-lymphocytes is not 
supported through a mimotope vaccine. In cancer, the 
mimotopes induce biological activities similarly to the original 
monoclonal antibody, including in vitro and in vivo growth 
inhibition, ADCC, CDC and ADCP. In the near future, 
mimotopes could be an alternative prophylactic, adjuvant 
and therapeutic strategy against allergy and cancer.
9.	 Expert	opinion
Although the term ‘immunotherapy’ is used in allergy and 
cancer, the meaning is different. Cancer immunotherapy 
mainly focuses on passive administration of monoclonal 
antibodies directed against a defined part of a tumour antigen, 
whereas generally in allergy, immunotherapy means the 
injection of whole-allergen extracts inducing allergen-specific 
non-responsiveness. A principle of SIT in allergy for down-
regulation the allergic hyper-responsiveness is the induction 
of blocking IgG antibodies, which should optimally be 
directed against IgE epitopes for successfully interfering with 
allergen–IgE interactions. Instead of whole allergen molecules, 
or even whole allergen extracts, it might be sufficient to perform 
immunotherapy with a subunit vaccine, such as mimotopes 
of B-cell epitope on the allergen.
The early trials using murine monoclonal antibodies for cancer 
therapy were accompanied by human anti-mouse antibody 
(HAMA) immune responses and relatively low efficacy due 
to the lack of effector functions of murine antibodies in con-
cert with human effector cells  [127]. Possibly connected with this 
problem at that time, much attention was rather given on the 
cytotoxic T-cell-dependent immunity. However, these therapies 
have limitations as tumour cells have developed escape strat-
egies to avoid T-cell responses, such as downregulation of 
HLA  [128,129]. Moreover, the applicability of T-cell-based peptide 
vaccines is restricted to the patient’s HLA haplotype.
In the meantime, antibody immunotherapies have, due 
to technical advances, made considerable progress: currently 
chimeric and humanized monoclonal antibodies with 
minimal antigenicity are applied as passive immunothera-
peutics, mostly in combination with chemotherapy. A 
major advantage of passive immunotherapy is that it can be 
turned off at any time point. Disadvantages are side effects 
(most often delayed-type hypersensitivity infusion reactions 
mostly due to the high antibody load leading to immune 
complex formation  [130]), but also the high costs. To offer an 
alternative choice and to improve quality of life for the 
patients during the course of tumour disease, vaccination 
should be considered.
With mimotope vaccines, complete-self-antibodies with the 
desired epitope specificity can be induced representing a 
continuously available, polyclonal antibody response. Although 
the anti-mimotope antibodies are dominated by a certain subclass 
depending on the route, formulation and cytokine environment 
of the vaccine, the overall immune response is constituted 
by several isotypes mediating several immune effector mecha-
nisms. So far, promising animal studies are available, and pre-
clinical and clinical studies are on the way. We suggest that 
minimal residual disease or prophylactic approaches in high-risk 
patients will be the favourable setting. These studies may 
break the ground for active tumour immunotherapy according 
to the successful concept of vaccines against infectious diseases.
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CHAPTER II 
Aims  
The overall aim of this study was to develop alternative therapeutic strategies for HER-2 
overexpressing tumours based on IgE antibodies. HER-2 was chosen as tumour target because 
it is overexpressed in several human tumours, which is associated with a poor prognosis and 
an aggressive course of disease. The state of the art therapy for HER-2 overexpressing cancers 
is trastuzumab, an IgG1 monoclonal antibody. Although trastuzumab proved to be highly 
effective in clinical use, there are still some problems that have to be solved, concerning the in 
vivo stability, the tissue penetration and distribution, the recruitment of effector cells, the half-
life and the costs of these therapies. Concerning these drawbacks an antibody of the IgE 
subclass with the same specificity would have several advantages. 
Therefore, we aimed to investigate the role of IgE in addition to its well-known function in 
helminth infections and allergy. Considering the high capacity of IgE for mediating 
disadvantageous but potent inflammatory reactions, we were interested in the possible 
function of IgE in tumour surveillance. By specifically targeting IgE to tumour antigens in an 
active or passive approach, these reactions could be harnessed and directed towards malignant 
cells.  
The first aim was to establish an oral immunization regime in a murine model to actively 
induce antigen-specific IgE antibodies (CHAPTER III). For this purpose, we applied 
ovalbumin, the major egg white allergen, under concomitant anti-acid medication and 
investigated the subsequent antibody response. By elevating the gastric pH, normally 
digestion-labile proteins remain stable and lead to the formation of antigen-specific IgE. Sera 
of the BALB/c mice were screened for allergen-specific antibody titres and their according 
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isotypes. The biological activity of IgE was tested in RBL assays and the clinical relevance 
was investigated by skin prick tests.          
As our second and major aim was to improve the drawbacks of trastuzumab mentioned above, 
we focussed on the active induction of tumour-specific IgE via mimotope approach 
(CHAPTER IV) and on the generation of a trastuzumab-like antibody of the IgE subclass for 
passive immunotherapy (CHAPTER V).  
The methodology and knowledge from our food allergy study was applied in an anti-cancer 
study which is presented in CHAPTER IV. Here, our aim was to use epitope mimics 
(mimotopes) of HER-2 for vaccination purposes to induce trastuzumab-like antibodies in an 
active manner. Feeding mice with the mimotope, under the same conditions as described in 
CHAPTER III, result in the induction of anti-HER-2 IgE antibodies of trastuzumab specificity 
and similar biological function. Importantly, we aimed to test the tumouricidic activity of the 
induced HER-2-specific IgEs in a cytotoxicity assay using HER-2 overexpressing cells as 
targets.  
However, for detailed experimental comparison of anti HER-2 IgE versus IgG, we considered 
it important to have defined tools in our hands. Therefore, we decided to generate a 
trastuzumab-like IgE. We aimed to clone the epsilon part in place of the constant gamma part 
of the original trastuzumab (CHAPTER V). The newly engineered IgE was assessed in 
comparison with original trastuzumab in respect of i) binding characteristics to HER-2 and its 
receptors and ii) their respective killing capacities against HER-2 overexpressing tumour cells 
(ADCC and ADCP).  
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CHAPTER III 
Dose-dependent food allergy induction against ovalbumin under acid-suppression: A 
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Background: Animal models are essential for analyzing the allergenic potential of food proteins and for
investigating mechanisms underlying food allergy. Based on previous studies revealing acid-suppression
medication as risk factor for food allergy induction, we aimed to establish a mouse model mimicking the
natural route of sensitization in patients.
Methods: The effect of acid-suppressing medication on murine gastric pH was assessed by intragastric
pH measurements after two injections of a proton pump inhibitor (PPI). To investigate dose-dependency,
mice were fed different concentrations of ovalbumin (OVA; 0.2, 0.5, 1.0, 2.5 or 5.0mg) either with or
without anti-ulcer medication. Additionally, different routes of exposure (i.p. vs. oral) were compared in
a second immunization experiment. Sera were screened for OVA-speciﬁc antibody titers (IgG1, IgG2a and
IgE) in ELISA and RBL assay. Clinical reactivity was evaluated by measuring rectal temperature after oral
challenge and by type I skin tests.
Results: Two intravenous injections of PPI signiﬁcantly elevated the gastric pH from 2.97 to 5.3. Only
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54oral immunization with 0.2mg OVA under anti-acid medication rendered elevated IgG1, IgG2a and IgE
titers compared to all other concentrations. Protein feeding alone altered antibody titers only marginally.
Even though also i.p. immunizations induced high levels of speciﬁc IgE, only oral immunizations under
anti-acids induced anaphylactic reactions evidenced by a signiﬁcant decrease of body temperature.
Conclusion: Only low-dosage ovalbumin feedings under anti-acid medication resulted in IgE mediated
food allergy. Based on this knowledge we have established a suitable food allergy model for further
erse r
tinvestigations of food adv
. IntroductionToday, population studies indicate a rising prevalence of food
llergies in western societies [1,2]. Consequently there is a growing
eed to investigate in-depth mechanisms and risk factors leading
Abbreviations: OVA, ovalbumin; PPI, proton pump inhibitors; SGF, simulated
astric ﬂuid; SDS-PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis;
.v., intravenous; i.p., intraperitoneal; i.g., intragastric; Al(OH)3, aluminum hydrox-
de; ELISA, enzyme-linked immunosorbent assay; TBST, Tris buffered saline with
ween-20; DMP, dried milk powder; TMB, tetramethylbenzidine; RBL, rat basophil
eukaemia; 4-MUG, 4-methylumbelliferyl-d-galactopyranoside; HRP, horseradish
eroxidase.
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athophysiology and Immunology, Medical University of Vienna, Waehringer Guer-
el 18-20, E3Q, 1090 Vienna, Austria. Tel.: +43 1 40400 5121;
ax: +43 1 40400 5130.
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o sensitization towards food compounds. For this purpose, ani-
al food allergy models including rodent, swine and dog models
re used and discussed to have the potential to mimic the human
isease process [3]. Additionally, in the 2001 joint FAO/WHO meet-
ng animal models were suggested as suitable tools for the analysis
f the allergenic potential of novel dietary compounds [4], which
hould be further evaluated for structural homologies or sequence
imilarities with known allergens, included in allergy testing and
hould be assessed for their digestion stability [5].
Despite signiﬁcant differences between human and mouse
mmunology [6],mice are the preferentially used organism for food
llergy models. A wide range of inbred strains have been char-
cterized as being either high or low IgE responder animals [7].
he easy handling and the possibility to include a larger number
f animals per group account for the widespread use. Important
or these studies are immunological similarities between mice and
umans as both produce IgE antibodies, which bind to the high
fﬁnity receptor FcRI being expressed onmast cells and basophils.
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nboth species gastrointestinal symptomsdependon synthesis and
ecretion of serotonin and platelet-activating factor [8].
Recently, we have developed a novel oral immunization proto-
ol in BALB/c mice inducing an IgE mediated response by protein
eedings under concomitant anti-acid medication [9–11]. In these
tudies, the normal function of the stomach representing a gate-
eeper against food allergens has been determined as an important
actor for preventing food allergies [12].
The relevance of this mechanism was demonstrated both in the
urine system[9–11] aswell as for humans, as 25%of gastroentero-
ogical patients being treated with acid-suppression medication
or a 3-month period due to dyspeptic disorders revealed forma-
ion of speciﬁc IgE antibodies and sensitization towards dietary
ompounds [9,13].
Based on this knowledge we aimed to establish a true mouse
ood allergy model exploiting the oral route for immunizations
nder concomitant acid-suppression treatment. The major egg
hite allergen ovalbumin (OVA), a 45kDa protein constituting
bout 54% of all egg white proteins, was chosen as a model antigen
ue to its wide use in allergy research to enable a better compari-
on with previously established food allergy models. Moreover, we
anted to standardize our immunization regimen addressing the
ffect of dose-dependency on food allergy induction.
. Materials and methods
.1. The model allergen ovalbumin
Lyophilized OVA (Sigma, Vienna, Austria, 98% purity) was used
or all experiments. Simulatedgastric ﬂuid (SGF)waspreparedwith
pharmaceutical enzyme tablet (Enzynorm® forte, Pharmaselect
andels GmbH, Vienna, Austria) as previously described [14] with
light modiﬁcations: one tablet was dissolved in 100L 0.9% ster-
le sodium chloride at pH 2.0 or pH 5.0. For digestion, 500L of
GF was incubated with 500g OVA. The digestion was quenched
ith 0.1N NaOH after 1, 5, 15, 60 and 120min. The effect of incuba-
ionwith SGF on protein integritywas evaluated in SDS-PAGE using
oomassie brilliant blue staining [15].
.2. Animals
Four to six weeks old female BALB/c mice were purchased
rom the Institute of Laboratory Animal Science and Genet-
cs, Medical University of Vienna, Austria. All experiments were
erformed according to European Community rules of animal
are (permission numbers GZ 66.009/0039-BrGT/2005 and GZ
6.009/0170-BrGT/2006 of the Austrian FederalMinistry of Science
nd Research).
.3. Intragastric pH measurements after acid-suppression
Six weeks old female BALB/c mice were divided into two groups
n=10). After overnight fasting mice were either left untreated or
ere injected intravenously (i.v.) with the proton pump inhibitor
meprazole (PPI, Losec®, AstraZeneca GmbH, Wedel, Germany;
16g omeprazole diluted in 0.9% sodium chloride), which was
ollowed by a second i.v. injection after 1h. After 15min, mice were
acriﬁced and the stomachwas immediately removed andperfused
ith 150L sterile sodium chloride. The pH of this washing ﬂuid
as measured using a pH microelectrode.
hapter III 
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For investigating the effect of antigen dosage, animals were
ivided into 10 groups (n=5 each). Based on the data generated by
T
I
a
w
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ntragastric pH measurements groups 1–5 were medicated intra-
enously with the proton pump inhibitor for 3 days (on days 1–3,
6–18 and 29–31). On days 2–3, 17–18 and 30–31micewere immu-
ized orally with different concentrations of OVA (0.2, 0.5, 1.0, 2.5,
.0mg per mouse) mixed with 2mg sucralfate (Ulcogant®, Merck)
5min after a repeated i.v. injection of the PPI. Groups 6–10 were
ed the allergen at the different concentrations without PPI on the
espective days. Blood samples were taken on days 0, 15, 28 and
2.
To compare different routes of exposure, the immunization
xperiments were repeated with four groups of animals (n=10
ach). Group A was immunized intraperitoneally (i.p.) with 2g
VAadsorbed to 2%aluminumhydroxide solution (1.3gAl(OH)3).
roup B (0.2mg OVA i.g. under acid-suppressing medication) and
roup C (0.2mg OVA i.g.) were immunized following the same
rotocol with the previously selected concentration. The negative
ontrol Group D remained naïve.
All immunizations were performed in two independent sets of
xperiments.
.5. Evaluation of OVA-speciﬁc antibodies in ELISA, RBL-assay
nd dot blot experiments
Murine serawere screened forOVA-speciﬁc antibody subclasses
IgG1, IgG2a) in an enzyme-linked immunosorbent assay (ELISA).
icrotiter plates (Maxisorp, NUNC, Roskild, Denmark) were coated
ith 1g OVA per well. After blocking with TBST (Tris buffered
aline with Tween-20) with 1% dried milk powder (DMP), mouse
era diluted 1:100 for IgG1 and IgG2a in TBST/0.1% DMP were incu-
ated overnight at 4 ◦C. Bound antibodies were detected using rat
nti-mouse IgG1 and IgG2a (BD Biosciences, Franklin Lakes, NJ;
:500) followed by a peroxidase labeled goat anti-rat IgG (Amer-
ham, Buckinhamshire, UK, diluted 1:1000). For detection, TMB
tetramethylbenzidine, BD Bioscience, Vienna, Austria) was added
or 15min and the reaction was stopped with 1.8M H2SO4. The
olor reaction was measured at 450–630nm. Antibody concentra-
ions were calculated according to standard dilution series after
ubtracting levels detected in pre-immune sera as background val-
es.
To evaluate biologically active OVA-speciﬁc IgE, a rat basophil
eukemia cell assay (RBL-assay) was performed [16]. RBL-
H3 cells, exclusively expressing the high afﬁnity IgE receptor
cRI [17], were passively sensitized with murine sera (dilution
:10) and incubated at 37 ◦C for 1h. After washing, 10g/mL
VA were added to the appropriate wells. The induced -
exosaminidase release was detected using 4-methylumbelliferyl
-d-galactopyranoside (4-MUG, Sigma, Vienna, Austria) and the
uorescence was measured at 360–465nm. Calculation was
ade by correlating measured values with -hexosaminidase
elease of cells lysed with triton-x (Sigma), which was set
00%.
In order to evaluate the binding capacity of OVA-speciﬁc
gE antibodies to undigested antigen and to OVA digested for
20min either at pH 2 or pH 5 conditions, dot blot experi-
ents were performed. Therefore, 1g of the appropriate antigen,
ither OVA or as control -casein, were dotted onto nitrocellu-
ose membranes (Life Sciences Bio Trace, Pall Corporation, Vienna
ustria). After blocking with 1% DMP in TBS 0.1% Tween blot
tripes were incubated with serum samples taken before the
rst and after the last immunization (1:500 diluted in TBS 0.1%
___________________________________________________ween) for 2h. After extensive washing, ﬁrst rat anti-mouse
gE (1:1000) and after 1h peroxidase labeled goat anti-rat IgG
ntibodies (1:3000) were added for detection. The blot stripes
ere developed by luminescence reaction using the ECL kit
Amersham).
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Fig. 1. Impaired OVA digestion at elevated pH levels of SGF. OVA (lane 1) was incu-
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(group 1–5). For an additional Th2 biasing effect [19], the alu-
minum containing anti-acid sucralfate was added to the solution,
which was fed the animals. To further address the question of
dose-dependency, we have used different OVA concentrations (0.2,
0.5, 1.0, 2.5 and 5.0mg per mouse) for the feedings. As controls,
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.6. In vivo read-out by rectal temperature measurement after
ral antigen challenge and type I skin testing
On day 49, animals were fed with 2mg OVA in PBS (oral chal-
enge) for evaluating anaphylactic reactions. Rectal temperature
as measured before and 15min after oral challenge with a ther-
ometer (Thermalert TH5, Clifton, NJ).
To evaluate the in vivo relevance of the induced OVA-speciﬁc
ntibodies, type I skin tests were performed on day 50. 100L
f 0.5% Evans Blue (w/v) were applied intravenously. 0.6g of
VA and the control antigen -casein, both diluted in sterile
odium chloride were injected intradermally into the shaved
bdominal skin. The mast cell degranulation compound 48/80
Sigma, 20g) was used as positive and sterile sodium chloride
s negative control. After 20min, animals were sacriﬁced and
he color reaction was evaluated on the inside of the abdominal
kin.
.7. Cytokine determination
As previously described [11], spleen cells were removed under
terile conditions, minced and passed through sterile nylon ﬁl-
ers (cell strainer 40m Nylon). Erythrocytes were lysed in 0.75%
mmonium chloride (3mL) for exactly 4min. After stopping the
eaction cells were washed for 3 times in medium. Cell number
as determined in a Coulter Counter. For spleen cell stimula-
ion, 4×105 cells per well were incubated at 37 ◦C in triplicates
ith OVA (20g/mL), medium (as negative control) or con-
anavalin A (as positive control; 50g/mL) for 4 days. Thereafter,
00L spleen cell supernatants were withdrawn for evaluation
f cytokine levels and were screened for IL-5 and IFN- using
capture ELISA (eBioscience Ready-set-go! IL-5 or IFN- Femto
S, San Diego, CA) following the manufacturer’s instructions. In
hort, after coating the appropriate capture antibody, plates were
locked with assay diluent for 1h. Either standard (recombinant
ouse IL-5 or IFN-) or mouse spleen cell supernatants were incu-
ated for 2h. After extensive washing, a biotin-labeled detection
ntibody was added. After 1h incubation with avidin-HRP, the
eaction was developed using a substrate solution (TMB-solution)
or 15min and the absorbance was read at 450–570nm. Compar-
sons were performed by calculating concentrations according to
standard curve after subtracting medium values as background
evels.
.8. Data analysis
Antibody titers, RBL-assay and cytokine results were statisti-
ally compared using the non-parametric Mann–Whitney U test.
H measurements and temperature results were compared using
he two-tailed Student’s t-testwith theSPSS14.0program.APvalue
.05 was considered statistically signiﬁcant.
. Results
apter III 
__________________________________________________.1. Digestion stability of OVA to simulated gastric ﬂuid
In linewith previously published data [18], SGF digestion of OVA
sing a pharmaceutical enzyme tablet revealed that OVA proteins
ere degradedwithin 60min of gastric digestion at pH2.0 (Fig. 1A).
owever, by increasing the pH conditions to pH 5.0 the protein
ands remained stable up to 120min (Fig. 1B), representing the
verage gastric transit time.
F
n
p
1
w
dated with pepsin for 1, 5, 15, 60 and 120min either at pH 2 (panel A) or pH 5
panel B). All proteins were degraded after 60min of digestion at pH 2. However, by
ncreasing the pH of the simulated gastric ﬂuid to pH 5 all proteins remain stable up
o 120min.
.2. Two injections with a proton pump inhibitor signiﬁcantly
ncreases the gastric pH
To evaluate the effect of PPI medication on the murine gastric
nvironment, we performed intragastric pH measurements after
wo i.v. injections of the PPI omeprazole. As depicted in Fig. 2,
he gastric pH levels increased signiﬁcantly from pH 2.97 in the
ntreated animals (group A) to pH 5.30 measured 15min after the
econd PPI injection (group B).
.3. OVA feeding under acid-suppression induces antigen-speciﬁc
ntibodies in a dose-dependent manner
Based on the results from intragastric pH measurements, we
ave medicated mice intravenously with the PPI on 3 consec-
tive days for 3 times and further immunized orally with OVAig. 2. Repeated anti-acid medication elevated intragastric pH levels. Compared to
aïve animals (group A), mice being medicated twice intravenously with the proton
ump inhibitor (group B) showed a signiﬁcant increase of intragastric pH already
5minafter the second injection. Theboxes represent the innerquartiles value range
ith themedian indicated as black line. Brackets indicate the statistically signiﬁcant
ifference of intragastric pH (*P< .05).
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Fig. 3. OVA-speciﬁc antibody induction in acid-suppressed mice. Acid-suppressed animals (1–5) or BALB/c mice without anti-acid medication (group 6–7) were fed different
concentrations of OVA (0.2mg: groups 1 and 6; 0.5mg: groups 2 and 7; 1.0mg: groups 3 and 8; 2.5mg: groups 4 and 9; 5.0mg OVA: groups 5 and 10). Only acid-suppressed
mice receiving 0.2mg OVA showed signiﬁcantly increased levels of IgG1 and IgG2a (panel A and B). Comparing the effect of i.p. immunization with oral feeding (panel C and
D) higher levels of IgG1 and IgG2a were observed in the positive controls (group A; OVA i.p.) and to a lesser extent in the acid-suppressed animals (group B; OVA i.g. + PPI).
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57 o changes in antibody titers were observed in mice fed the protein alone (group C
mmune serum, middle grey; third immune serum, light grey) represent the inner
.5-fold interquartile range deviation from the end of the box were deﬁned as outlie
ere deﬁned as extremes and marked with asterisks. Brackets indicate statistically
ice were fed the respective OVA concentration without acid-
uppression (group 6–10). In the medicated animals, the IgG1 and
gG2a levels were signiﬁcantly increased only in group 1 being fed
.2mg OVA under acid-suppression (Fig. 3A and B). Interestingly,
mmunizations with all other allergen concentrations (0.5, 1.0, 2.5
r 5.0mg per gavage) did not elevate antibody titers even under
oncomitant anti-acid therapy. In the second set of experiments,
omparing different routes of immunization, especially the posi-
ive control group A (OVA i.p.) developed high levels of both IgG
ubtypes and to a lesser extent also the acid-suppressed animals
f group B. Nevertheless, differences in IgG1 levels were observed
etween groups 1 and B in the two sets of experiments. Animals
eing fed the OVA proteins alone (Group C) and naïve mice (Group
) showed no altered antibody levels (Fig. 3C and D).
In a RBL assay, murine sera taken after the last immunization
ere assessed for functional antigen-speciﬁc IgE antibodies. Only
he acid-suppressed animals being fed 0.2mg OVA showed signif-
cantly increased -hexosaminidase release compared to all other
mmunization concentrations (Fig. 4A). These ﬁndings were con-
rmed in the second set of experiments, where a signiﬁcantly
levated -hexosaminidase release was observed in the positive
t
w
c
win the naïve animals (group D). The boxes (ﬁrst immune serum, dark grey; second
iles value range with the median indicated. Sera with signals showing more than
marked as circles. Sera with titers lying more than 3-fold interquartile range away
cant differences of antibody concentrations (**P< .01).
ontrol groupA and after oral immunizationswithOVAunder acid-
uppression (Group B) (Fig. 4C).
Dot blot experiments were performed to evaluate the binding
apacity of speciﬁc IgE antibodies to undigested OVA and further
o OVA digested either at pH 2.0 or pH 5.0. In accordance with the
BL assay results, only IgE of the animals being fed 0.2mg OVA
nder acid-suppression and themice being injectedOVA i.p. bound
peciﬁcally to undigested OVA and to the protein being digested at
levated pH conditions. Only background reactivity was observed
ith proteins digested at pH 2 for 120min. Neither sera obtained
rom other groups (Fig. 4B and D) nor preimmune sera (data not
hown) revealed binding reactivity with the dotted OVA samples.
.4. Decreased body temperature and positive skin testing reveal
ood allergy in animalsTo assess shock symptoms causing blood centralization and,
herefore, a decline of body temperature, the rectal temperature
as measured in immunized animals before and after oral provo-
ation with OVA. Only the animals which were immunized orally
ith 0.2mg OVA under anti-acid medication revealed a signiﬁ-
S.C. Diesner et al. / Immunology Letters 121 (2008) 45–51 49
Fig. 4. Biologically active IgE was induced in mice under anti-ulcer medication. Gavages of 0.2mg OVA under anti-acid treatment (lane 1) induced signiﬁcantly higher IgE
levels compared to other groups (lanes 2–10) (panel A). Intraperitoneal immunizations (group A) and oral injection under acid-suppression (group B) revealed signiﬁcantly
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58 igher values of speciﬁc IgE compared to feeding OVA alone (group C) and naïve anim
ice (group A) and the acid-suppressed animals being fed 0.2mg OVA (lanes 1 an
ther groups only background reactivity was observed. The IgE binding was diminis
ant decline in body temperature 15min after the oral challenge
P=0.046), whereas all other groups receiving the antigen via the
ral route showed only a marginal decrease or even an increase
f body temperature (data not shown). These data were con-
rmed in the second set of experiments. Despite the high levels
f IgE antibodies detected in the sera of animals of group A (OVA
.p.) a signiﬁcant decrease of body temperature was detected only
n group B immunized with OVA under anti-ulcer medication
Fig. 5).
To evaluate the in vivo relevance of detected antibodies, type I
kin testswere performed in the immunized animals. Only animals
mmunized with 0.2mg OVA under acid-suppression showed pos-
tive skin reactions to OVA, whereas no other oral immunization
rotocol revealed any reactivity to the tested allergens. Intraperi-
oneal immunization resulted in positive skin reactions only to
VA and to the positive control (compound 48/80), whereas naïve
f
i
t
d
i
ig. 5. Acid-suppressed animals revealed a signiﬁcant decrease of body temperature af
nimals fed OVA alone (group C) and the naïve animals (group D), only group B (0.2mg OVA
ndicate the statistically signiﬁcant differences of rectal temperature before and 15min afroup D) (panel C). In dot blot experiments (panels B and D) only the i.p. immunized
vealed IgE binding capacity to undigested OVA and OVA digested at pH 5.0. In all
hen testing with OVA digested at pH 2.0. Representative dot blots are shown.
nimals did not develop any skin reactivity except to the positive
ontrol antigen (Fig. 6).
.5. Antigen feeding under gastric acid-suppression induces Th2
ytokine production
In order to evaluate apossible Th2 switch inducedbyoral immu-
ization under anti-ulcer medication, spleen cell supernatants of
ice from the second experiment were screened for IL-5 as a
h2 marker, and IFN- as a Th1 marker. Compared to the animals
eing fed OVA alone, the i.p. immunized mice developed a 20-
old increase and the acid-suppressed animals revealed a 12-fold
ncrease of mean IL-5 levels, although differences were not sta-
istically signiﬁcant. The IL-5 levels of naïve animals were below
etection limits. In contrast, the IFN- levels of the animals being
njected OVA i.p. and of the mice being medicated with anti-ulcer
ter oral OVA challenge. Compared to the positive control (OVA i.p., group A), the
i.g. with anti-acids) revealed a signiﬁcant decrease of rectal temperature. Brackets
ter oral OVA challenge (**P< .01) within group B.
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Table 1
Cytokine levels measured in OVA stimulated spleen cell supernatants
Group A OVA i.p. Group B i.g. + antacid Group C OVA i.g. Group D naïve
IL-5
Mean 69.47 40.62 3.34 0
95% conﬁdence interval 12.30–126.65 0–101.08 0–8.51 0–0
IFN-
140.
–348.
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59 Mean 109.34
95% conﬁdence interval 0–271.87 0
ytokine concentrations are given as mean and 95% conﬁdence interval in pg/mL.
rugs were twofold increased compared to animals being fed the
ntigen alone and to naïve animals (Table 1).
. Discussion
Recently,wewere able to show that acid-suppression treatment
nterfering with gastric digestion of proteins in murine as well as
uman studies leads to IgE induction and food allergy [9–11,13].
he intake of anti-acid medication, e.g. sucralfate or proton pump
nhibitors, results in an elevation of the gastric pH. Under these cir-
umstances, normally digestion-labile proteins remain stable and
heir conformation intact, which enhances the possibility for de
ovo sensitization and formation of antigen-speciﬁc IgE [12].
The aim of the current study was to experimentally investigate
nderlying mechanisms and to compare our murine model of food
llergy with other immunization protocols and further to evaluate
he dose-dependency of antigen under acid-suppression.
For this purpose, we have chosen OVA as a model antigen. Even
hough OVA is generally accepted as a typical class 1 allergen being
f high stability to thermal and enzymatic degradation [20], it
as previously reported to be degraded within 60min in simu-
ated gastric ﬂuid experiments [18]. Indeed, also in our SGF assays
sing a pharmaceutical gastric enzyme tablet these data could be
onﬁrmed. However, if physiological low pH conditions (pH 2.0)
ere changed to pH 5.0 which is found after 5 days of treatment
ith proton pump inhibitors [21] OVA proteins remain stable up to
20min representing the normal gastric transit time. Interestingly,
part from protein fragmentation, gastric digestion was addition-
lly described to substantially change the immunological behavior
m
d
p
r
c
ig. 6. Feedings of OVA under acid-suppression induced positive type I skin tests. Group 1
kin reactions to OVA (top right) and the positive control compound 48/80 (bottom left)
o skin reactions were found in the acid-suppressed animals fed OVA with other conce
epresentative skin tests are shown. The skin test injection scheme is depicted in the righ43 67.37 68.64
31 0–177.17 0–195.49
f OVA by altering its biochemical features [22] and was shown
o have impact on antigen presentation [23]. Therefore, we sug-
est OVA as suitable and highly relevant model food protein for our
mmunization protocol.
In a ﬁrst experimentwewanted to conﬁrm the acid-suppressing
ffect of PPIs on themurinegastric environment. Already twocycles
f i.v. PPI injections signiﬁcantly elevated the intragastric pH of
ALB/c mice from 2.97 to 5.30. Thus, having a similar effect as on
he human pH levels [21] we have used repeated injections of PPI
n our immunization protocol. We additionally combined it with
ucralfate, as aluminum-compounds are known to establish a pro-
ounced Th2 response [24], which was recently also evidenced
or sucralfate [19,25]. As both drugs were previously reported to
nduce a Th2 biasing effect only in combination with the respective
llergen [9,11,19], we expected a profound Th2 induction by this
mmunization protocol.
In aﬁrst set ofmurine immunizationsweaddressed thequestion
f dose-dependency on allergy induction. It has been previously
eported that high doses of allergens are known to induce tol-
rance rather than sensitization [26]. Even though results might
e inﬂuenced by chosen mouse strains, it was demonstrated that
eedings of high concentrations of OVA (20–100mg) suppressed
ntigen-speciﬁc IgG1, IgG2a and IgE antibody levels [27]. However,
t was further described that rather low doses of OVA (0.25mg)
ay also render a reduction in IgE levels [28]. Furthermore, low
oses of OVA feedings (0.4–0.5mg) did not induce speciﬁc IgE
roduction when given without adjuvant [29]. In line with these
esults, feedings of OVA alone did not induce sensitization at any
oncentration. Whereas recent data revealed feedings of low con-
(0.2mg OVA i.g. with anti-acids) and the i.p. immunized animals revealed positive
, but no reactions to sodium chloride (top left) and the control antigen (-casein).
ntrations (2–5), in the mice fed the protein alone (6–10) or in the naïve animals.
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entrations of OVA (0.2 and 1mg) with cholera toxin as adjuvant
referentially induced antigen-speciﬁc IgG1 [30], we could show
hat gavages of the lowest dose of OVA (0.2mg) under concomi-
ant acid-suppression resulted in signiﬁcantly higher formation of
ntigen-speciﬁc IgG1, IgG2a and IgE compared to exclusive OVA
eedings. Furthermore, only this immunization protocol with the
owest antigendose revealeda signiﬁcantdropofbody temperature
fter oral OVA challenge.
We applied the concentration of 0.2mg OVA in a second
et of murine immunizations for comparing different routes of
mmunization. Therefore, we included a positive control of i.p.
mmunization and compared the induced antibodies with the lev-
ls observed in naïve animals. Here we could conﬁrm the humoral
mmune response upon OVA feeding under anti-acid treatment,
nderlined by elevated IgG1 titers and biologically functional IgE.
lso the positive controls developed high levels of all antibody
ubclasses, which is in line with previous studies [31,32]. Compa-
able to this route, even subcutaneous immunizations with OVA
dsorbed to aluminumhydroxidewere reported to induce high lev-
ls of IgG1 and IgE [33,34]. Furthermore, in our experiments both
mmunization regimens, i.p. injection of OVA and feeding under
cid-suppression rendered formation of the Th2 cytokine IL-5 and
dditionally revealedpositive type I skin tests toOVA,whereasmice
eing fed OVA alone and naïve animals did not show skin reactions
pon allergen testing.
Most importantly we observed a signiﬁcant reduction of body
emperature after oral antigen challenge only in the animals immu-
izedwith lowdosage of OVAunder concomitant acid-suppression
Fig. 5). The measurement of body temperature has since long
een applied for the read-out of anaphylactic reactions in numer-
us studies [35–37]. Interestingly, the induction of an anaphylactic
eaction upon oral antigen challenge exclusively in the acid-
uppressedanimalsmight result fromthe induced titersofdifferent
llergen-speciﬁc antibody isotypes. It has been hypothesized that
he lack of a clinical reactivity following i.p. immunization with
luminum as an adjuvant could be due to existence of blocking
ntibodies of the IgA and IgG subclass [8].
Basedon thecurrentdatawesuggestourmurinemodel to repre-
ent an experimental food allergymodelmimicking the situation in
llergic patients and conﬁrming the dose-dependent sensitization
apacity of allergens, again under acid-suppression [9,13]. Thus, we
ay have a valid model in our hand for further investigations of
echanisms in food allergy and for safety testing of novel dietary
ompounds.
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Abstract
A role of IgE antibodies in cancer surveillance has been
implicated for a long time. Studies dealing with IgE antibodies
directly targeted to tumor antigens have shown marked
anticancer effects mediated by this antibody class. Thus, the
basic function of IgE antibodies may be to control tumor
growth. Thus far, cancer-specific IgE has only been applied
passively. Consequently, the aim of this study was to establish
an active vaccination protocol to induce tumor antigen–
specific IgE antibodies, and to evaluate functional properties.
We previously generated epitope mimics, so-called mimo-
topes, for the epitope recognized by the anti-HER-2 antibody
trastuzumab. Upon i.p. immunizations, IgG antibodies with
trastuzumab-like properties could be elicited. In the present
study, we immunized BALB/c mice via the oral route with
these trastuzumab mimotopes, under simultaneous neutrali-
zation and suppression of gastric acid. As shown in preceding
experiments, this feeding regimen effectively induces Th2
immune responses. Oral immunizations with trastuzumab
mimotopes under hypoacidic conditions indeed resulted in
the formation of IgE antibodies towards the HER-2 antigen.
Moreover, anti-HER-2 IgE-sensitized effector cells mediated
SK-BR-3 target cell lysis in an antibody-dependent cytotoxicity
assay. We conclude that directed and epitope-specific induc-
tion of IgE against tumor antigens is feasible with an oral
mimotope vaccination regimen, and that these antibodies
mediate anticancer effects. [Cancer Res 2007;67(7):3406–11]
Introduction
The concept of immune surveillance was first proposed almost a
century ago by Paul Ehrlich (1), and as immunosurveillance
hypothesis against malignant disease, was again put forward in
1957 by Francis McFarlane Burnet (2). It suggests that the immune
system is continuously searching for and destroying tumor cells as
they arise. Evidence for the immune surveillance theory in humans
derives from the observation that those who are immunosup-
pressed exhibit a higher incidence of malignancy (3).
Early on, it was suggested that those with a history of allergy, in
particular atopic disorders, may possess an enhanced capacity for
immune surveillance. Beginning in 1953, with the study by Logan
and Saker (4), and around the 1960s (5–7) and early 1970s (refs.
8–12, reviewed in ref. 13), the first observations were published
that allergy could be inversely associated with cancer development.
For several decades, epidemiologic studies have tried to correlate
the incidence of allergic disease and diverse tumors, however,
the results were mostly controversial and depended on the type of
malignancy. In 2005, Turner et al. published the first large
prospective cohort study to examine the relationship between
atopic disease and cancer mortality, including 1,102,247 U.S. men
and women for 18 years of follow-up (14). In this study, they found
significantly lowered risks of f10% for overall cancer mortality
and 20% for colorectal cancer mortality among persons with a
history of both asthma and hay fever. A history of hay fever alone
was associated with a significantly lowered risk of pancreatic
cancer mortality, and a history of asthma only was associated with
a lowered risk of leukemia mortality.
Also in 2005, Wang and Diepgen published a review of the
epidemiologic studies after 1985 (15). Their general conclusion was
that allergy is associated with a reduced risk for cancer. This stands
especially for colon cancer, pancreatic cancer, childhood leukemia,
and brain tumors.
In 2006, the Turner group published another overview of the
epidemiologic evidence by using the MEDLINE database since 1966
(16). Again, strong inverse associations were reported for allergy
and pancreatic cancer and glioma, whereas lung cancer was
positively associated with asthma.
This evidence relates to conditions with overall elevated IgE
levels. Only a small number of studies have thus far investigated the
effects of tumor-specific IgE (17–21). All of them came to the
conclusion that IgE directly targeted to cancer antigens is
extremely efficient in eliciting antitumor effects. In 1991, Nagy
et al. developed a murine monoclonal IgE against the murine
mammary tumor virus. It was applied for passive immunizations of
mice, and prevented the development of s.c. tumors in an antigen-
specific fashion (17). Kershaw et al. also developed a monoclonal
IgE, recognizing a colon carcinoma antigen, and were the first to
prove that the antitumor effect of targeted IgE was isotype-
dependent (18). In 1999, Gould et al. generated mouse-human
chimeric IgG1 and IgE monoclonal antibodies against the ovarian
cancer antigen MOv18 and compared them in a severe combined
immunodeficiency mouse xenograft model of ovarian carcinoma.
They found that the beneficial effects of tumor-specific IgE were
greater and of longer duration than those of IgG1 (19). In a
subsequent study, this group showed that IgE triggered antibody-
dependent cellular cytotoxicity (ADCC) via monocytes (20). The
last study dealing with IgE directly targeted to tumor antigens
postulated that IgE loaded onto tumor cells could affect tumor
immunogenicity by activation of the innate immune system
directly at the tumor site. They used a biotin-avidin bridging
strategy to target IgE to the tumor cells, and found that IgE
strongly affects tumor growth in vivo , leading, in some cases, to
complete tumor rejection and protection against subsequent
tumor challenges by a mechanism involving both eosinophils and
Requests for reprints: Erika Jensen-Jarolim, Department of Pathophysiology,
Medical University of Vienna, Wa¨hringer Gu¨rtel 18-20, A-1090 Vienna, Austria. Phone:
43-1-40400-5120; Fax: 43-1-40400-5130; E-mail: erika.jensen-jarolim@meduniwien.ac.at.
I2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-06-3758
Cancer Res 2007; 67: (7). April 1, 2007 3406 www.aacrjournals.org
Research Article
Chapter IV 
______________________________________________________________________________________________________
62 
T cell–mediated antitumor responses. Moreover, the results showed
that IgE targeted to tumor cells not only possess curative potential,
but also confer long-term antitumor immunity (21).
From all these data, we believe that IgE, especially IgE targeted
to tumor antigens, plays a beneficial role in antitumor immunity.
Therefore, we aimed to move the approaches of passive
application of tumor-specific IgE a step forward—by developing
a vaccine that would induce tumor-specific IgE in vivo . To this
end, we combined two strategies that were developed in our
group during the past few years: first, an epitope-specific
vaccination against the HER-2 tumor antigen, rendering anti-
bodies with similar biological properties as the monoclonal
antibody trastuzumab (22); second, an oral immunization regimen
discovered in food allergy research, resulting in IgE induction
(23, 24). Here, we show for the first time the active induction of
tumor-specific IgE antibodies, targeting HER-2 as an important
model antigen.
Materials and Methods
Cell lines and monoclonal antibody. The HER-2-positive human
mammary carcinoma cell line SK-BR-3 (ATCC HTB-30) was grown in
McCoy’s medium (Life Technologies, Inchinnan, United Kingdom) supple-
mented with 10% FCS, 1% glutamine, 1% penicillin/streptomycin, and
50 Ag/mL of gentamicin sulfate. The human squamous carcinoma cell line
A-431 (CRL-1555; American Type Culture Collection, Manassas, VA), which
is HER-2-negative, was grown in DMEM (Life Technologies) supplemented
as above, and used for control purposes.
Rat basophilic leukemia RBL-2H3 cells were kindly supplied by Dr. Arnulf
Hartl, Paracelsus Medical University, Salzburg, Austria. They were grown in
RPMI 1640 (Life Technologies), supplemented with 10% FCS, 4 mmol/L of
L-glutamine, 2 mmol/L of sodium pyruvate, 10 mmol/L of Hepes, 100 Amol/L
of 2-mercaptoethanol, and 1% penicillin/streptomycin. Trastuzumab
(Herceptin), a humanized IgG1 monoclonal antibody targeting HER-2, was
purchased from Roche (Hertfordshire, United Kingdom).
Mimotope characterization and vaccine compound. Mimotopes
mimicking the trastuzumab epitope on HER-2 were previously defined
(22, 25). The best peptide mimic of these experiments, the 1,12-cyclic
peptide C-QMWAPQWGPD-C, was manufactured synthetically (piChem,
Graz, Austria) and coupled via its COOH terminus to a succinimidyl-4-
(N-maleinimidomethyl)cyclohexane-1-carboxylate activated immunogenic
carrier, keyhole limpet hemocyanin (KLH), through a linker (GPGPG) by
S-acetyl-thio-acetate. The conformational accuracy of the coupled mim-
otope was verified with specific recognition by trastuzumab. As a control,
the peptide 1,12-cyclic C-DGGWLSKGSW-C, which did not bind to
trastuzumab, was produced and coupled in the same way.
Immunization of BALB/c mice. Six-week-old female BALB/c mice
(n = 7 per group) were obtained from the Institute for Laboratory Animal
Science and Genetics (University of Vienna, Vienna, Austria) and were
treated according to European Community rules of animal care with
permission no. 66.009/35-BrGT/P2004 from the Austrian Federal Ministry of
Education, Science, and Culture.
Mice were immunized according to the oral immunization regimen for
IgE induction developed in our group (23), with some modifications.
Amounts of antiulcer drugs were correlated with the dosage recom-
mended for use in humans and adjusted for body weight and metabolism
of mice. Each animal received 11.6 Ag of omeprazole (Losec, AstraZeneca,
Vienna, Austria) i.v. on days 1, 2, and 3 of each immunization cycle. On
day 3, omeprazole was applied 2 h and 15 min before intragastric
immunization. One hundred micrograms of the respective antigen were
mixed with 2 mg of sucralfate (Ulcogant; Merck, Vienna, Austria) and
administered intragastrically in a final volume of 100 AL. The verum group
was immunized with the C-QMWAPQWGPD-C mimotope-KLH conjugate,
and the control group received the carrier KLH alone. Immunizations
were done on days 3, 17, 45, 59, and 87. Blood was taken from the tail vein
on day 0 (preimmune serum), and on days 27, 69, and 97 ( first, second,
and third mouse immune serum).
Titer determination. IgE and IgG titers of sera from the immunized
BALB/c mice against KLH and against the mimotope peptide were
determined by incubation of serial dilutions of pooled group sera with
DotBlots of KLH, the C-QMWAPQWGPD-C mimotope peptide, and the
control peptide C-DGGWLSKGSW-C. In short, antigens were solubilized
in PBS/20% dimethylformamide, and dotted onto nitrocellulose
membrane at 1 mg/mL. Blot strips were incubated with mouse serum
dilutions, and bound antibodies detected with rat anti-mouse IgG or rat
anti-mouse IgE antibodies (PharMingen, San Diego, CA), that were
again detected by a peroxidase-conjugated sheep anti-rat immunoglo-
bulins (Amersham Pharmacia Biotech, Little Chalfont, United Kingdom)
using the ECL chemoluminescent detection protocol (Amersham).
Trastuzumab was used as a positive control and detected with a
peroxidase-conjugated goat anti-human IgG antibody (Jackson Immu-
noResearch, West Grove, PA). Titers were given as the highest serum
dilution at which antigen reactivity was still detectable in these DotBlot
experiments.
B-Hexosaminidase release assay from RBL-2H3 cells. RBL-2H3 cells,
which express rodent FcqRI as their only antibody receptor, were used to
determine functional HER-2–specific IgE. Cells were incubated with
individual third immune sera of the mimotope-immunized or the control
mice to allow for binding of serum IgE to FcqRI. Loaded RBL-2H3 cells were
then incubated with SK-BR-3 cells as a source of natural HER-2, or with
A-431 cells as controls. IgE recognition of its target antigen leads to cross-
linking of FcqRI, rat basophilic leukemia (RBL) cell degranulation, and thus,
h-hexosaminidase release. Released enzyme was detected by 4-methyl-
umbelliferyl-N-acetyl-h-D-glucosaminide (4-MUG), and the resulting fluo-
rescence measured at 465 nm (excitation wavelength 360 nm). For 100%
release, RBL cells were lysed with Triton X-100, and relative experimental
releases determined as follows:
% hexosaminidase release ¼ experimental release spontaneous release
maximum release spontaneous release  100
Antibody-dependent cytotoxicity assay. The ADCC potential of the IgE
antibodies induced by mimotope vaccination was assessed with a modified
CytoTox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI).
SK-BR-3 and A-431 cells were used as target cells; with A-431 cells as
controls. The number of target cells was optimized to 2  105 cells/mL
according to the instructions of the manufacturer. For the ADCC experi-
ments, an effector to target (E/T) ratio of 100:1 was found to yield optimal
specific lysis in a series of preliminary tests. RBL-2H3 cells were used
as effector cells, after ascertaining that even at full ionomycin-induced
degranulation, these cells do not release lactate dehydrogenase, the indicator
of target cell lysis measured by a color reaction in this ADCC assay. Ten
microliters of the third immune sera of the mimotope-immunized or the
control mice were used for ADCC experiments. All assay procedures and
readouts were done according to the instructions of Promega. The
percentage of cytotoxicity was calculated after correcting for background
absorbance values according to the following formula:
% cytotoxicity ¼ experimental effector spontaneous target spontaneous
target maximum target spontaneous  100
Maximal cytotoxicity caused by fully degranulated RBL cells against SK-
BR-3 cells was set to 100% RBL-mediated lysis, and resulting cytotoxicities
were adjusted accordingly. All titer determinations, h-hexosaminidase
release, and ADCC assays were done in triplicate, and repeated for
reproducibility.
Statistical analyses. Statistical analyses were done using two-tailed
Student’s t test, as immune responses in syngeneic mice were considered to
be distributed normally. P < 0.05 was considered statistically significant, and
P < 0.01 was considered highly statistically significant.
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Results
Immune responses against the vaccine construct induced by
oral mimotope vaccination. Mice were immunized with the
mimotope C-QMWAPQWGPD-C or the carrier molecule KLH as
shown in Fig. 1. As mimotopes on their own are too small to elicit
an immune response, the immunogenic carrier KLH was used in
designing the vaccine construct (26, 27). Groups were further
designated as ‘‘QMW-KLH’’ and ‘‘KLH.’’ To ensure hypoacidity
during the gastric passage, mice received the proton pump
inhibitor omeprazole once daily 2 days preceding each immuni-
zation, and twice on the day of immunization. Additionally, the
antigens were dispersed in the protective film-building ulcer
medication sucralfate. This combined regimen has been shown to
effectively elevate gastric pH,5 and lead to the formation of IgG and,
importantly, IgE antibodies against food proteins fed under these
conditions (23, 24). In contrast, proper digestion of dietary proteins
favors immune tolerance or ignorance (28).
IgG and IgE titers against the carrier and trastuzumab mimotope
were determined by DotBlot analysis. IgG titers reached a plateau
after two courses of two immunizations, as no booster effect
was seen between the second and third immune serum (see Fig. 1;
Table 1). IgE was only first observed after these four immuniza-
tions, and could be boostered by an additional immunization
(Table 1). A representative example of a DotBlot titer determina-
tion can be seen for the third immune sera in Fig. 2. Interestingly,
both IgG and IgE responses were stronger against the mimotope
than the carrier (in the case of IgE, there was no response against
the carrier detectable at all, see Table 1).
IgE formation against the original antigen, HER-2. As shown
in our previous work, a crucial point in mimotope immunizations
is the induction of antibodies not only recognizing the applied
mimotope, but also the original antigen that is mimicked. For
anti-HER-2 IgG antibodies, we could show this cross-reactivity in
Western blots (22). For IgE antibodies induced by the oral
vaccination regimen, we employed another experimental setup.
We applied an assay commonly used in allergology, i.e., a release
assay from RBL cells. These cells only carry the high-affinity
receptor for IgE, FcqRI, and can thus be used to determine IgE
levels in sera in which a high content of IgG antibodies against the
same antigen would otherwise interfere in assay sensitivity. When
specific IgE is bound to the high-affinity receptors, and brought in
contact with cognate antigen, FcqRI cross-linking and RBL
degranulation occurs. The released enzyme h-hexosaminidase
can be detected by a fluorescence reaction, and corresponds with
the specific IgE content of the applied sera.
To show that the induced antibodies recognize the mimicked
original antigen, HER-2, we used the HER-2–overexpressing breast
cancer cell line SK-BR-3 as the source of antigen in the RBL assay.
The HER-2-negative squamous cell carcinoma cell line A-431 was
used as a negative control. IgE from mice immunized with QMW-
KLH consistently led to highly significant degranulation of RBL
cells after incubation with SK-BR-3 cells, but not with A-431 cells.
KLH-immunized mice showed no reactivity with either cell line
(Fig. 3). This indicates that the induced antimimotope IgE
antibodies indeed specifically recognize the tumor antigen HER-
2. Additionally, a successful RBL release assay was the first hint of
the functionality of the induced IgE antibodies, as they have been
shown to be capable of cross-linking FcqRI molecules.
IgE-mediated cytotoxicity. To further investigate the biological
effects of the induced anti-HER-2 IgE antibodies, we adapted a
classic nonradioactive cytotoxicity assay. RBL cells were used as
effector cells, and sensitized with IgE from individual third immune
sera from the QMW-KLH- and KLH-immunized mice. In this RBL
ADCC assay, the mimotope-induced IgE antibodies exhibited RBL-
mediated lysis in the range of 20% to 100% of SK-BR-3 cells (Fig. 4).
RBL-ADCC ranging from 0% to 55% was seen with antibodies from
the KLH-immunized control group. Although these ranges are
broad and overlapping, the difference was found to be statistically
significant (P V 0.01). When antimimotope antibodies were tested
on A431 control cells, no specific cytotoxicity was observed (data
not shown).
Discussion
The physiologic role of IgE antibodies is still not fully
understood. Nevertheless, evidence is accumulating that these
antibodies could be involved in the prevention of malignant disease
Figure 1. Oral immunization regimen. Timeline of antacid medication, antigen gavage, and blood sampling.
Table 1. Antibody titers of mimotope-immunized mice
against the mimotope and the carrier protein
IgG IgE
QMW KLH QMW KLH
Preimmune serum — — — —
First immune serum 1:1,000 1:1,000 — —
Second immune serum 1:10,000 1:5,000 1:100 —
Third immune serum 1:10,000 1:5,000 1:500 —
5 E. Untersmayer, unpublished data.
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(14–16). IgE is present in only low concentrations in the serum of
normal individuals (f30 ng/mL; ref. 18), but is highly increased in
two situations: the case of parasite infestation and in allergic
disease. For both conditions, there is evidence of a negative
association with cancer: Experimental data from mice show that
animals infested with nematodes were resistant to syngeneic
mammary adenocarcinoma (29), or showed decreased incidence of
spontaneous mammary tumors (30). Huge epidemiologic studies
and metaanalyses have been conducted on the topic of atopic
disease and cancer risk, and a significant, if small, negative
association has been found (14–16). The latest bit of evidence for
the inverse association between allergy and malignant disease
stems from the first clinical trials with the anti-IgE monoclonal
antibody, omalizumab. Omalizumab is a human/murine chimeric
monoclonal IgG antibody that prevents IgE from attaching to
effector cells, thereby blunting IgE-mediated inflammatory
responses. It is known to result in a marked reduction in serum
levels of free IgE and down-regulation of IgE receptors on
circulating basophils. When IgE was inhibited with this anti-IgE
antibody, 1 in 200 asthmatic patients developed breast, skin,
prostate or parotid gland malignancies during the median
observation period of 1 year, whereas in the control group, the
incidence was 1:500.6
The picture becomes clearer when one focuses on IgE specific
for cancer cell antigens. There are early observations of ‘‘natural’’
IgE-mediated mechanisms in cancer patients. In 1977, Rosenbaum
and Dwyer pointed out that evidence was published prior to the
recognition of IgE that suggested that IgE may recognize tumor-
specific antigens (13). A study in cancer patients in 1958 reported
that eight tumor patients ( five breast, two Hodgkin’s, one
lymphoma) showed wheal and flare skin reactions upon intrader-
mal injections of lysates of their own tumor. This apparently was
an immediate hypersensitivity response typically mediated by IgE.
Moreover, this reaction could be transferred to a healthy volunteer
in a classic Prausnitz-Ku¨stner reaction (31). In 1972, Bartholo-
maeus and Keast observed that mice could produce IgE specific for
a tumor, in this case, B16 melanoma (32).
Four groups have thus far targeted IgE to tumor-specific
antigens, i.e., the mouse mammary tumor virus (17), a surface
antigen of human colorectal carcinoma (18), the ovarian cancer
antigen MOv18 (19, 21), and—via biotin-avidin bridging—to a
lymphoma and an adenocarcinoma antigen (20). All found that IgE
antibodies directly targeted to tumor antigens—in contrast with
overall elevated IgE levels—cause a marked effect on tumor
development and growth. For example, monoclonal IgE raised
against murine mammary tumor virus were able to protect
syngeneic mice from a lethal dose of mammary carcinoma cells
(17), and as little as 1 Ag of colon carcinoma–specific IgE per
mouse was sufficient to inhibit COLO 205 tumor growth (18).
However, all these strategies used passive applications of IgE. A
vaccination regimen aimed at active induction of tumor-specific
IgE seemed to be a promising approach.
Recently, we have developed an active immunization regimen for
inducing tumor-inhibitory antibodies against HER-2, which is a
member of the epidermal growth factor receptor (also known as
the ErbB) family. This receptor is overexpressed inf30% of breast
cancer patients and confers a detrimental prognosis in the course
of early as well as advanced breast cancer (33). The monoclonal
antibody trastuzumab (Herceptin) targets this receptor, and
Figure 2. Oral immunization under acid suppression with the mimotope
conjugate elicits IgE antibodies recognizing the immunogen. Mice were
immunized with C-QMWAPQWGPD-C–KLH (QMW-KLH ) or KLH alone. IgE titer
determination by DotBlot against the peptide C-QMWAPQWGPD-C, and
against a control peptide. Serum dilutions are shown.
Figure 3. Mimotope-induced IgE antibodies recognize the original antigen,
HER-2, expressed on SK-BR-3 breast cancer cells. In a h-hexosaminidase
release assay with RBL-2H3 cells, IgE from mice immunized with
C-QMWAPQWGPD-C–KLH (QMW-KLH ) led to significant degranulation of
RBL cells after incubation with HER-2–overexpressing SK-BR-3 cells, but not
with the HER-2-negative control cell line, A-431. KLH-immunized mice show no
reactivity with either cell line. Box plots, median, 25th, and 75th percentiles of
h-hexosaminidase release mediated by sera of individual mice in each group
(n = 7). This release correlates with the anti-HER-2 IgE levels of the respective
groups. Both the difference of the mimotope-immunized group in SK-BR-3/A-431
recognition, as well as the difference between mimotope and control group in
SK-BR-3 recognition, were found to be highly statistically significant (P < 0.01)
by two-tailed Student’s t test.
6 Food and Drug Administration Briefing Document on Safety BLA STN 103976/0.
http://www.fda.gov/ohrms/dockets/ac/03/briefing/3952B1_02_FDA-Xolair-Safety.pdf.
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beneficially influences the progression of early and advanced HER-
2 overexpressing tumors. Consequently, we used trastuzumab to
generate peptide mimics (so-called mimotopes) of its binding site
on HER-2. These mimotopes induced trastuzumab-like IgG anti-
bodies in mice upon parenteral (i.p.) immunization. Importantly,
these actively induced antibodies showed similar biological
antitumor features as the original antibody itself (22).
A second experience in our group stems from our research on
food allergy mechanisms. We found that food proteins can
effectively lead to IgE formation and sensitization when they
persist the gastric passage undegraded (28). Gastric digestion is
impaired in conditions of hypoacidity as, e.g., under antiulcer
treatment. Consequently, an oral immunization regimen was
developed that leads to the induction of a Th2 bias, i.e., high
levels of food protein–specific IgG and IgE antibodies, eosinophilia,
and hypersensitivity of skin and mucosa, when antigens are fed
under concomitant gastric acid suppression (23, 24, 34).
In the present study, we combined our two fields of experience,
and could show that feedings of trastuzumab mimotopes under
antiacidic conditions indeed induced HER-2–specific IgE in BALB/c
mice. These antibodies proved to be functional in an allergologic
mediator release assay, where mimotope-induced IgE was found to
react highly-specifically with HER-2–overexpressing breast cancer
cells. To the best of our knowledge, this is the first active induction of
tumor-specific IgE in vivo .
IgE is known to be capable of mediating ADCC of parasitic
larvae in combination with effector cells bearing FcqRI. Indeed,
these mechanisms play a major role in immune defense against
parasites (35). Thus, IgE specifically targeted to tumor antigens
could function in a similar way: by cross-linking FcqRI it would
activate potent effector cells. Already in the first study on tumor-
specific IgE, it was hypothesized that IgE-mediated cytotoxic
mechanisms may play an immunologically specific antitumor
surveillance role (17). Gould et al. also thought that IgE could
mediate anticancer ADCC, and therefore created chimeric IgE
and IgG1 antibodies recognizing an ovarian cancer antigen to
directly compare between the two subclasses. Indeed, in their
in vivo model, only IgE, and not IgG1 caused sustained inhibition of
tumor growth until the end of the experiments (day 48). The
inhibitory effect of tumor-specific IgE was substantial (83%) and
highly significant (19). In a more recent publication, they were able
to show that humanmonocytes were active in IgE-dependent ADCC
in vivo . Tumor cell killing was proportional to the expression of
FcqRI on monocytes, and they observed phagocytosis of tumor cells
by the monocytes in vitro . Testing basophils, they observed targeted
exocytosis of the granules at the site of contact with cancer cells,
and overall, an accumulation of basophils at the site of tumors (21).
We therefore did an assay evaluating the ADCC-mediating
potential of the induced anti-HER-2 IgE antibodies towards breast
cancer cells. As effectors, we used the rat basophilic leukemia cell
line RBL-2H3, which expresses the rodent FcqRI as its only antibody
receptor. Thus, we were sure that no other antibodies contained in
the immune sera could interfere in this assay. These cells were
incubated with individual serum samples of mimotope and KLH
immunized mice. Indeed, specific IgE-mediated lysis of target
cells could be observed. The degree of IgE-ADCC mediated by the
sera correlated with the level of HER-2-specific IgE detected by the
h-hexosaminidase assay.
Generally, IgE may have two major advantages over other
isotypes in the therapy of cancer. One aspect may be the prolonged
duration of antitumor effects. Whereas the serum half-life of
unbound IgE in humans is onlyf2 days, the half-life of IgE in skin
is in the order of several months (36). Thus, IgE-mediated effector
functions at tissue tumor sites could be expected to last for a
long time. The extended lifetime of receptor-bound IgE may allow
cells to locate and kill tumor cells in solid tissues more effectively
than IgG.
The second aspect is the high affinity of the interaction between
the Fc portion of IgE and FcqRI, which may allow effective arming
of potential effector cells that would then be able to extravasate
and penetrate tissue without losing surface-bound antibody (18).
Indeed, it is well known that there is an infiltration of developing
tumors by various FcqRI-bearing immune cells. More importantly,
on-site production of IgE by plasma cells could contribute to
beneficial effects. Indeed, a high number of IgE-positive cells was
found in most squamous cell carcinomas of the head and neck
when compared with normal mucosa (37).
In general, the special role of IgE is to act as a very potent
inducer of mediator release and cytokine production from
eosinophils, basophils, macrophages, and mast cells. Among the
released substances are histamine, heparin, the enzymes tryptase
and chymase, as well as the proinflammatory cytokines granulocyte
macrophage colony-stimulating factor, interleukin 4, interleukin 5,
and tumor necrosis factor a (38, 39). Moreover, several lines of
evidence indicate a crucial role for eosinophils and macrophages in
tumor eradication through a mechanism involving the production
of reactive oxygen metabolites and nitric oxide (20). But in humans,
it has to be considered that the high-affinity receptor FcqRI is also
expressed on antigen-presenting cells as Langerhans cells and
monocytes (40). IgE is capable of mediating antigen capture,
processing, and presentation by professional antigen-presenting
cells, facts known from allergic patients. Thus, IgE-driven
antitumor activity is not restricted to the activation of innate
Figure 4. HER-2–specific IgE antibodies lead to SK-BR-3 breast cancer cell
lysis via ADCC mechanisms. In a nonradioactive cytotoxicity assay, IgE-loaded
RBL cells were used as effector cells. Mimotope-induced IgE antibodies
targeting HER-2 mediated significant ADCC lysis of SK-BR-3 cells, when
compared with control sera from KLH-immunized mice. Box plots, median, 25th,
and 75th percentiles of relative target cell lysis (n = 7 per group). The difference
between verum and control group was found to be statistically significant
(P < 0.05) by two-tailed Student’s t test.
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immunity effector mechanisms, but could also initiate efficient
antigen presentation and thus priming of a T cell–mediated
adaptive immune response (41). It is likely that IgE antibodies
trigger an inflammatory reaction at the tumor site by recruitment
and activation of FcqR-bearing effector cells, which in turn, may
favor tumor cell destruction, an essential requirement for efficient
priming of CD4- and CD8-dependent immune responses (42, 43).
Taken together, there is growing evidence that IgE might have a
role in cancer surveillance and suppression. The negative
association between cancer incidence and conditions with elevated
IgE levels could indicate that atopic individuals possibly have some
antitumor protection due to a tendency to form IgE antibodies,
and among them, the beneficial tumor-specific ones as well. The
slightly increased cancer risk seen in patients exposed to the anti-
IgE antibody omalizumab6 might thus be explained by both a
reduction of possible tumor-specific IgE antibodies, but even more
so, by its reduction of FcqR-bearing effector cells.
We conclude that IgE specifically targeted to tumor antigens
elicits effective antitumor immune responses and that it is feasible
to induce tumor antigen–specific IgE antibodies by active
immunization.
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Abstract Trastuzumab (Herceptin®), a humanized IgG1
antibody raised against the human epidermal growth factor
receptor 2 (HER2/neu), is the main antibody in clinical use
against breast cancer. Pre-clinical evidence and clinical
studies indicate that trastuzumab employs several anti-
tumour mechanisms that most likely contribute to enhanced
survival of patients with HER2/neu-positive breast carcino-
mas. New strategies are aimed at improving antibody-based
therapeutics like trastuzumab, e.g. by enhancing antibody-
mediated eVector function mechanisms. Based on our
previous Wndings that a chimaeric ovarian tumour antigen-
speciWc IgE antibody showed greater eYcacy in tumour
cell killing, compared to the corresponding IgG1 antibody,
we have produced an IgE homologue of trastuzumab. Trast-
uzumab IgE was engineered with the same light- and
heavy-chain variable-regions as trastuzumab, but with an
epsilon in place of the gamma-1 heavy-chain constant
region. We describe the physical characterisation and
ligand binding properties of the trastuzumab IgE and eluci-
date its potential anti-tumour activities in functional assays.
Both trastuzumab and trastuzumab IgE can activate mono-
cytic cells to kill tumour cells, but they operate by diVerent
mechanisms: trastuzumab functions in antibody-dependent
cell-mediated phagocytosis (ADCP), whereas trastuzumab
IgE functions in antibody-dependent cell-mediated cytotox-
icity (ADCC). Trastuzumab IgE, incubated with mast cells
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70 and HER2/neu-expressing tumour cells, triggers mast cell
degranulation, recruiting against cancer cells a potent
immune response, characteristic of allergic reactions.
Finally, in viability assays both antibodies mediate compa-
rable levels of tumour cell growth arrest. These functional
characteristics of trastuzumab IgE, some distinct from those
of trastuzumab, indicate its potential to complement or
improve upon the existing clinical beneWts of trastuzumab.
Keywords HER2/neu · Trastuzumab · IgE · Monocytes · 
Mast cells · Tumour immunity
Abbreviations
HER2/neu Human epidermal growth factor receptor 2
ADCC Antibody-dependent cell-mediated 
cytotoxicity
ADCP Antibody-dependent cell-mediated 
phagocytosis
FBP Folate binding protein
sFcRI Soluble FcRI -chain
ECDHER2 HER2 protein extracellular domain
CM Complete medium
PI Propidium iodide
CFSE Carboxy-Xuorescein diacetate, succinimidyl
ester
NIP 4-Hydroxy-3-nitro-phenacetyl
PI3K Phosphoinositide 3-kinase
TGF-a Tumour growth factor 
VEGF Vascular endothelial growth factor
TNF- Tumour necrosis factor-
MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt)
PMS Phenazine methosulfate
Introduction
HER2/neu (c-erb-B2) is a 185 kDa protein that belongs to
the human epidermal growth factor receptor family. Its
functions include engendering cell signalling and regulat-
ing cell growth, proliferation, diVerentiation and motility
[1]. Approximately 30% of breast carcinomas as well as
other cancers, such as those of the ovary, endometrium,
bladder, prostate and lung, over-express HER2/neu, whilst
its expression in normal tissues is low [2]. Its expression in
breast cancer is thought to play a vital role in the pathogen-
esis of breast tumours and is linked to poor clinical out-
comes [3]. This antigen is now a validated target for cancer
therapeutics.
Trastuzumab (Herceptin®) is an IgG1 antibody raised
against the extracellular domain (ECD) of HER2/neu and is
the main antibody in clinical use for the treatment of
HER2-positive breast cancers [4–6]. Trastuzumab was
approved by the FDA in 1998 for the treatment of meta-
static HER2/neu over-expressing breast cancer and is now
also used as adjuvant therapy for early breast cancers. The
success of trastuzumab in breast cancer therapy has
renewed interest in antibody therapies and provoked further
research into the development of therapeutic antibodies.
However, only a subset of patients treated with trastuzumab
show signiWcant responses and thus there is scope for addi-
tional modalities designed to improve clinical outcomes [7].
Trastuzumab is thought to exert anti-tumour eVects by a
number of mechanisms. The best-deWned mechanism is the
blocking of the hetero-dimerization of HER2/neu receptors
with other HER family members (HER1, HER3) on the
surface of breast cancer cells thereby switching oV vital
tumour cell growth signals [8, 9]. Trastuzumab inhibits
metalloproteinase activity and interferes with signalling via
phosphoinositide 3-kinase (PI3 K) pathways, promoting
apoptosis and cell cycle arrest during the G1 phase.
Another mechanism is thought to be blocking angiogenesis
by inducing expression of anti-angiogenic factors such as
thrombospondin-1 and suppression of pro-angiogenic fac-
tors such as TGF-, VEGF, angiopoietin-1, and plasmino-
gen-activator inhibitor-1 [10]. Clinical and pre-clinical
studies suggest that trastuzumab may also enlist immune
eVector cells to attack and kill tumour cells by cytotoxicity
(ADCC) and phagocytosis (ADCP), and by augmenting
chemotherapy-induced cytotoxicity [11–14]. Studies are
now focusing on strategies aimed at improving the signiW-
cant but circumscribed success of trastuzumab. These
include optimising antigen speciWcity or aYnity and
enhancing antibody-mediated eVector cell functions tar-
geted against tumour cells.
Although there are Wve antibody classes in man, each
with distinctive functions in the immune system, trast-
uzumab, but essentially all monoclonal antibodies approved
for clinical use are IgG1 s. Antibodies of the IgG class
function most eVectively in the circulation [15]. There are
many reasons why IgE antibodies might be more eVective
against tumours that develop in tissues and are therefore
inaccessible to IgGs [16]. The concentration of IgE in the
serum of normal individuals is minute (<150 ng/mL, 1/
10,000 the concentration of IgG) because IgE is seques-
tered in solid tissues, where it is bound with high-aYnity to
receptors on its eVector and antigen-presenting cells [17].
The aYnity of IgE for FcRI (Ka »1011 M¡1) is 102–105
times higher than those of IgGs for their receptors, making
IgE the only antibody strongly retained by eVector cells in
the absence of antigen [17, 18]. The half-life of IgE in tis-
sues (measured in the skin »2 weeks) is longer than that of
IgG (2–3 days) [18, 19]. IgE saturates FcRI at nM concen-
trations, but only 10% of the receptors need be occupied by
IgE and antigen for full mast cell activation and eVector cell123
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71 recruitment to the site of antigen challenge in tissues [17,
20]. IgE antibodies on the surface of tissue mast cells are
cross-linked by antigens to induce the release of histamines,
leukotrienes, proteases, and, importantly, Th2 cell-type
cytokines (IL-3, IL-4, IL-5, IL-6, IL-9, IL-13, TNF-) at
the site of antigen challenge. This results in activation of
the resident immune eVector cells, but also elicits further
recruitment and persistence of an inXammatory cell inWl-
trate, comprising Th2 cells, monocytes, eosinophils and
basophils, from the circulation, which enhances and main-
tains the local immune response [17]. IgE antibodies
directed against a tumour-associated antigen would there-
fore trigger an immediate local eVector cell response
against tumour cells and stimulate a cascade of inXamma-
tion targeted to the tumour cells in situ. These activities
could possibly be highly eVective in immune rejection of
tumours embedded in solid tissues.
Several studies support the ideas IgE antibodies may be
highly eVective tools in cancer therapy [21–28]. We have
previously shown that an antibody of the IgE class is supe-
rior to the corresponding IgG1 antibody against folate bind-
ing protein (FBP) in prolonging survival of mice in two
xenograft models of ovarian cancer [29–32]. Ours and other
studies [23, 27, 33–35] have contributed to the suggestion
that the antibody class may inXuence the nature as well as
the potency of the immune responses elicited against
tumour cells.
In order to examine the mechanisms by which an IgE
version of trastuzumab may act in tumour cell killing, we
have engineered a humanised trastuzumab IgE. Here, we
report the physical characterisation and functional proper-
ties of the engineered trastuzumab IgE, and show that these
properties are distinct from those of trastuzumab (IgG1).
Our data suggests that trastuzumab IgE may potentiate
tumour killing by mechanisms and pathways that might be
highly eVective in cancer therapy.
Materials and methods
Antibodies and reagents
Chimaeric mAbs MOv18 IgE and MOv18 IgG (IgG1 iso-
type) against the human folate binding protein (FBP), NIP
IgE speciWc for the hapten 4-hydroxy-3-nitro-phenacetyl
(NIP) and the recombinant IgE receptor FcRI alpha (sFc-
RI) were prepared as before [29, 36, 37]. ECDHER2, the
soluble human HER2 protein comprising the HER2/neu
extracellular domain (ECD) (90 kDa) was prepared as pre-
viously described [38]. Trastuzumab (Herceptin®) was
from Genentech (San Francisco, CA, USA), goat anti-
human IgE-FITC was from VECTOR Laboratories Ltd.
(Peterborough, UK) and anti-CD89-PE and anti-CD33-
APC mAbs were from BD Biosciences (Oxford, UK). Anti-
bodies to Fc and Fc receptors, human IgG isotype-
matched control and goat anti-mouse-Ig-FITC Abs were
from Dako (Glostrup, Denmark). PI, CFSE, and tissue cul-
ture reagents were from Invitrogen (Paisley, UK).
Generation of trastuzumab IgE antibody
The cDNA derived from the protein sequences of the heavy
and light chains of the trastuzumab variable regions was
synthesised (Gene Art AG, Regensburg, Germany) based
on the published protein sequence of trastuzumab (source:
http://www.pdb.org; 1n8z) [39]. This cDNA was then
cloned into two vectors based on a pTT vector backbone,
one containing the epsilon heavy chain of IgE (humighae2,
accession no: L00022; Kenten et al. 1982), the other con-
taining the human kappa light chain constant region cDNA
(IGKC, accession no: BC110394) [40, 41] (Fig. 1). For full
amino acid sequences for trastuzumab IgE see Supplemen-
tary Table I (Supplementary Data). For transfection into
compatible HEK293 cells, vector DNA was produced using
the HiSpeed Plasmid Maxi Kit® (Qiagen®), according to
the manufacturer’s instructions. HEK293 cells were har-
vested and seeded at 4 £ 105 cells/mL and allowed to
adhere before being transfected with 1 g of DNA with the
aid of 2 g of PEI (Polyethenylenimine, MW: 25 kDa;
Polysciences Inc., Warrington, PA, USA) per 4 £ 107 cells
[40]. Supernatants were harvested 2–4 weeks later and anti-
bodies were puriWed by aYnity chromatography as previ-
ously described [29]. Antibody purity was conWrmed by
HPLC analysis.
Fig. 1 Schematic representation of the design of trastuzumab IgE
antibody. To engineer trastuzumab IgE, the variable heavy and light
chains of trastuzumab (IgG1, left; regions indicated with stars) were
inserted into the epsilon heavy chain regions of IgE and the epsilon
heavy chain was combined with the kappa light chain to produce the
corresponding trastuzumab IgE antibody (right). The resulting engi-
neered IgE molecule should recognise the HER2/neu antigen and IgE
receptors (see Supplementary Table I, Supplementary Data for full
sequence). Glycosylation sites are depicted by black circles123
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72 Kinetic assays of antibody binding to HER2 and FcRI
Kinetic studies were performed using surface plasmon res-
onance (SPR) analysis to examine the speciWcities and
binding aYnities of trastuzumab (IgG1) and trastuzumab
IgE antibodies to the soluble ECDHER2 protein and to the
soluble high-aYnity IgE receptor alpha subunit (sFcRI),
each immobilised on the biosensor surface. Kinetics of
trastuzumab IgE binding to immobilised FcRI on the bio-
sensor surface were compared to the well-characterised chi-
maeric antibody NIP IgE. All experiments were performed
at 24°C on a Biacore 3000 instrument (Biacore Int. SA,
Switzerland). Methods and kinetic analysis have been
described previously [36, 42, 43]. In these experiments,
antibodies were tested at a concentration range of 125–7.8
nM, coupling density was typically restricted to 200RU,
Xow rate 20 L/min, and exposure time to analyte 360 s.
Cell culture
The human monocytic cell line U937 [44] (kindly provided
by Prof. J.-P. Kinet, Harvard University, Boston, MA, USA)
was grown in RPMI 1640 medium, 10% FCS, 2 mM l-gluta-
mine, penicillin (5,000 U/mL) and streptomycin (100 g/
mL). The murine colon adenocarcinoma cell lines CT26 [45,
46] and CT26-HER2/neuHer2+ transfected with the HER2/
neu antigen [47] were grown in Iscove’s medium (IMDM),
5% FCS, 2 mM l-glutamine, penicillin (5,000 U/mL) and
streptomycin (100 g/mL). The human breast adenocarci-
noma cell line SKBR3 (ATCC, No. HTB-30), that naturally
expresses the HER2/neu antigen, was grown in DMEM,
10% FCS, 2 mM l-glutamine, penicillin (5,000 U/mL) and
streptomycin (100 g/mL). The rat basophilic leukaemia
mast cell line RBL-SX38 [48] (Prof. J.-P. Kinet, Harvard
University, Boston, MA, USA) expresses the human form of
the FcRI receptor and was maintained in MEM supple-
mented with 10% FCS, 250 g/mL Geneticin, 2 mM l-gluta-
mine, penicillin (5,000 U/mL) and streptomycin (100 g/
mL). All cells were maintained at 37°C in 5% CO2.
Flow cytometric assessments of antibody binding 
to receptors on cells
For Xow cytometric assessments of antibody binding to the
tumour-associated antigens FBP and HER2/neu and to Fc
(IgE) and Fc (IgG) receptors on receptor-expressing cells,
cells were incubated with 0.5 g/mL mAbs for 30 min at
4°C, followed by two washes in FACS buVer (PBS, 5%
normal goat serum). Cells were then given anti-human IgE-
FITC or anti-human IgG-FITC (10 g/mL) for 30 min at
4°C, washed in FACS buVer and Wxed in 1% paraformalde-
hyde-FACS buVer prior to acquisition and analysis on a
dual laser FACSCalibur™ (BD Biosciences). For quantita-
tive assessments of Fc and Fc cell surface receptors,
2 £ 105 U937 cells/sample were stained with mouse mAbs
by indirect immunoXuorescence using the QIFIKIT®
(Dako). U937 cells, setup beads and calibration beads were
given goat anti-mouse IgG-FITC, followed by two washes
in FACS buVer and analysis by Xow cytometry on a
FACSAria II Xow system (BD Biosciences). The numbers
of receptors per cell were calculated against Xuorescent cal-
ibrating bead standards using linear regression.
Flow cytometric ADCC/ADCP assay
Treatment of tumour cells
We employed our previously described novel three-colour
Xow cytometric assay to simultaneously measure tumour cell
cytotoxicity (ADCC) and phagocytosis (ADCP) of HER2/
neu-positive tumour cells by human eVector cells [30, 31, 49].
CT26-HER2/neu or SKBR3 cells were stained 24 h prior to
assays with 7.5 M CFSE in PBS for 10 min at 37°C, washed
in RPMI 1640 medium, 10% FCS, 2 mM L-glutamine, and
returned to normal culture conditions. The following day,
CFSE-labelled tumour cells were washed, mixed with
unstained eVector cells at E:T ratio of 2:1 with or without anti-
bodies, followed by incubation for 2.5 h at 37°C. Antibodies
were tested at concentrations of 0.05, 0.5 and 5 g/mL.
Three-colour Xow cytometric assay setup
CFSE-labelled tumour cells were detected in FL1 (530/
30 nm band pass Wlter), PE-labelled monocytic eVector
cells in FL2 (582/42 nm band pass Wlter) and PI+ dead cells
in FL3 (670 nm LP band pass Wlter) channels, whilst con-
trol samples were set for compensation adjustments
between Xuorochromes. Two dual colour Xow cytometric
dot plots were generated to calculate ADCC and ADCP as
previously described [30, 31, 49]. BrieXy, one dot plot
depicted CFSE + tumour cells and PI + cells, allowing
quantitation of tumour targets killed externally by eVector
cells (ADCC, cytotoxicity) (CFSE +/PI + cells). The
second dot plot depicted CFSE + tumour cells and
CD89-PE + eVector cells in order to quantitate total
CFSE + tumour cells and the number of tumour cells
present within PE + eVector cells, depicting phagocytosis
(ADCP) by eVector cells (CFSE +/PE + cells) [49]. This
dot plot would also indicate any non-speciWc uptake of
CFSE Xuorescence by PE + U937 eVector cells.
Confocal imaging of cell contact and antibody-mediated 
tumour cell phagocytosis
U937 monocytes, which served as eVector cells, were
incubated on Lab-Tec II glass chamber slides (SLS Ltd,123
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73 Manchester, UK) with CFSE-labelled CT26-HER2/neu
tumour cells at an original E:T ratio of 2:1. Treatments
were performed as above. Mixed cell cultures were incu-
bated for 3 h with MOv18 IgG, MOv18 IgE, trastuzumab
(IgG1) or trastuzumab IgE antibodies. At the end of the
incubations, cells were then given anti-CD33-APC for
40 min at 4°C, to label monocytic cells. Cells were then
washed, Wxed in 4% paraformaldehyde-FACS buVer and
mounted with Xuorescence preserver (Dako). Fluores-
cence microscopy was performed on a Zeiss Axiovert
200 confocal microscope (63 £ oil immersion objec-
tive). Acquisition and analysis was performed with
UltraView software (PerkinElmer, Waltham, MA,
USA).
In vitro degranulation assays
The ability of the engineered trastuzumab IgE to trigger
degranulation was measured in vitro using the rat baso-
philic mast cell line RBL-SX38. This cell line expresses
the human form of the FcRI receptor as a 2 tetramer,
the form naturally expressed on the surface of human mast
cells [48, 50, 51]. For degranulation experiments cells
were plated at 2 £ 104 per well in 100 L in 96 well Xat-
bottomed tissue culture plates and incubated overnight at
37°C in a humidiWed CO2 incubator. The following day,
cells were sensitised with IgE diluted in culture medium at
100 ng/mL, incubated for two hours at 37°C and washed
twice with HBSS, 1% BSA (wash buVer). Cell degranulation
was triggered for 30 min either with 100 L of anti-human
IgE polyclonal rabbit mAb (Dako) (Wnal concentration:
100 ng/mL), or HER2/neu-expressing CT26 cells added at
diVerent concentrations (1 £ 103 to 5 £ 105 per well) in
wash buVer at 37ºC. Degranulation was terminated by
placing the cells on ice and the supernatants removed
for quantiWcation of mediator release. Control supernatants
were either from individual or mixed cell populations
alone treated with no antigen for background release, or
wash buVer plus 0.1% Triton-X-100 (Tx) for total release.
Degranulation was measured by quantiWcation of -hexos-
aminidase release, assayed using a Xuorogenic substrate
(4-methylumbelliferyl-N-acetyl--D-glucosaminide) pre-
pared according to a standard protocol [51, 52]. Superna-
tants were incubated in black 96 well plates with an equal
volume of substrate at 37°C for 2 h and quenched with
0.5 M Tris. Fluorescence was measured using a Thermo
Fluoskan II Wtted with a 350 nm excitation and a 450 nm
emission Wlters. All measurements were made in triplicate
for each concentration and release was expressed as a per-
centage of total content determined by treatment with 0.1%
Triton-X-100 solution in HBSS, 1% BSA. Background
release, subtracted from all values, was always <10% of
total release.
Cell viability assay
Tumour cell viability was analysed by the MTS assay
(tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium inner salt) using phenazine methosulfate (PMS) as a
reducing agent (CellTiter 96® AQueous One Solution Cell
Proliferation Assay kit, Promega, Southampton, UK). Cells
were seeded in 96-well plates at 4 £ 104 cells per well and
allowed to adhere overnight under standard culture condi-
tions prior to assays. Cells were exposed to 0.5 g/mL
trastuzumab, trastuzumab IgE, MOv18 IgG or MOv18 IgE
antibodies over a period of 4, 24, and 48 h. Control groups
received media alone, or 0.9% v/v Triton-X-100 for 30 min
prior to addition of MTS. Following treatments, MTS/PMS
solution prepared according to the manufacturer’s instruc-
tions were added at 20 L per well and cells were incubated
for a further 1 h prior to recording absorbance at 490 nm
with a 96-well plate reader. The quantity of formazan prod-
uct as measured by the amount of 490 nm absorbance is
directly proportional to the number of living cells in cul-
ture.
Data handling and statistical analysis
In surface plasmon resonance assays, mean values §SD
were calculated from three measurements. Flow cytometry
experiments of receptor binding and blocking were
repeated at least three times. In vitro ADCC/ADCP assays
were performed in triplicate and data are shown as mean
ADCC § SD and ADCP § SD of a number (n) of indepen-
dent experiments (see Supplementary Table II in Supple-
mentary Data). Statistical analyses of in vitro ADCC/
ADCP assays and microscopic measurements of eVector-
tumour cell interactions were performed by means of the
unpaired two-tailed Student’s t test, and signiWcance was
accepted at P < 0.05.
Results
Binding of trastuzumab IgE to antigen and FcRI
We have compared the kinetics of binding of the engi-
neered trastuzumab IgE and trastuzumab (IgG1) to HER2/
neu ECDHER2 immobilised on a biosensor surface by
surface plasmon resonance (Fig. 2a; Table 1). The two
antibodies exhibited similar rates of association and
dissociation from their complexes with ECDHER2 (ka, kd,
mean § SD, Table 1). These data demonstrate that trast-
uzumab IgE exhibits the expected interaction with
ECDHER2, and the calculated aYnity values of both trast-
uzumab IgE and IgG1 (Ka of 1010) are similar to those123
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74 previously reported for the IgG1 [6, 53]. Comparison of
sensograms representing binding of trastuzumab IgE and
the chimaeric NIP IgE to the immobilised soluble alpha-
chain of FcRI (sFcRI) demonstrates that both antibodies
bind to the high-aYnity IgE receptor with the expected
kinetics and aYnity (ka, kd, mean § SD; Fig. 2b; Table 1).
In particular, both antibodies demonstrate the documented
slow dissociation rate that is characteristic of the complex
of IgE with FcRI (Fig. 2b) [36, 42, 43]. As expected, trast-
uzumab (IgG1) did not bind to the IgE receptor (Fig. 2b,
right panel).
Trastuzumab interaction with receptors on monocytic 
eVector and tumour cells
Flow cytometric assessments of trastuzumab and trast-
uzumab IgE interactions with HER2/neu and Ig (Fc and
Fc) receptors on the surface of cells served two purposes.
The Wrst was to conWrm that the antibodies recognise their
native receptors as presented on cell surfaces. The second
was to explore the mechanisms employed by trastuzumab
and trastuzumab IgE together with human monocytic cells
to target and kill HER2/neu receptor-expressing tumour
cells. For this, we analysed the interactions of these anti-
bodies with U937 monocytic cells, which served as eVector
cells, and with the CT26 cells transfected to express the
human HER2/neu receptor on the cell surface (CT26-
HER2/neu) [46], used as target cells.
The expression of IgG receptors FcRI, FcRII and
FcRIII and of IgE receptors FcRI and CD23 on U937
cells were also measured (Table 2). U937 monocytes
express FcRI (»12,000 molecules per cell) and FcRII
(»19,000 molecules per cell) but very low levels of FcRIII
(»700 molecules per cell). In agreement with our previ-
ously published data [30], we measured approximately
22,000 molecules of FcRI are expressed per cell, whilst
the expression of CD23 was low (»2,200 molecules/cell).
Consistent with the abundant expression of Fc receptors
on the surface of U937 cells, trastuzumab bound to Fc
receptors expressed on the surface of 99.8% of U937 mono-
Fig. 2 Comparative SPR analy-
sis of trastuzumab IgE and trast-
uzumab (IgG1) kinetics of 
binding to immobilised HER2 
receptor ECDHER2 (a) and to im-
mobilised FcRI (b). Data were 
recorded using a Biacore 3000 
(Xow rate 20 L/min). Antibod-
ies were tested at concentrations 
ranging from 125 to 7.8 nM. All 
values derived from the Wtting 
procedures are given in Table 1
Table 1 Calculated kinetic values of trastuzumab IgE binding to HER2 and FcRI
Kinetic parameters and aYnity constants derived from the SPR analysis of NIP IgE and trastuzumab IgE binding to immobilised sFcRI and trast-
uzumab (IgG1) and trastuzumab IgE binding to immobilised ECDHER2. Both IgEs and trastuzumab were analysed using a 1:1 model of association
from which association and dissociation constants were derived for each component (shown § SD for at least Wve determinations in the concen-
tration range 125–7.8 nM)
Constant ECDHER2 surface sFcRI surface
Trastuzumab IgE Trastuzumab (IgG1) Trastuzumab IgE NIP IgE
ka (M¡1 s¡1) (3.5 § 1.4) £ 105 (7.3 § 3.5) £ 105 (4.8 § 2.3) £ 105 (2.3 § 1.1) £ 105
kd (s¡1) (2.4 § 0.3) £ 10¡5 (1.8 § 0.9) £ 10¡5 (2.3 § 0.5) £ 10¡5 (2.6 § 0.5) £ 10¡5
Ka (M¡1) 1.5 £ 1010 4.2 £ 1010 2.1 £ 1010 1.0 £ 1010123
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75 cytic cells (Fig. 3a, upper left), as did the chimaeric antibody
MOv18 IgG, speciWc for the ovarian tumour antigen FBP,
used as positive control (Fig. 3a, upper right). Trastuzumab
also bound to 79.8% of CT26-HER2/neu cells (Fig. 3a, bot-
tom left), whilst only background binding of the MOv18
IgG was detected (5.2%) (Fig. 3a, bottom right). These data
conWrm the speciWcity of the antibody for the human HER2/
neu antigen expressed on the surface of tumour cells as well
as to the Fc receptors expressed by monocytic cells.
Trastuzumab-mediated killing of tumour cells
We employed our previously developed three-colour Xow
cytometric assay to simultaneously measure trastuzumab
ADCC and ADCP of HER2/neu-expressing tumour cells
[49] (Fig. 3b, c). The CT26-HER2/neu cells were used as
tumour targets and human U937 monocytes were employed
to provide eVector cells. The green-Xuorescent dye CFSE
was used to stain live CT26-HER2/neu cells prior to incu-
bation with U937 monocytes and, after the incubation,
U937 cells were stained with anti-CD89-PE and dead cells
with propidium iodide (PI). Two colour Xow cytometric dot
plots show that after 2.5 h in culture, U937 cells mixed with
trastuzumab and CT26-HER2/neu mediated little ADCC
above that seen with samples incubated with the MOv18
IgG (5.3 vs. 4.8%; Fig. 3b, top panels, top right boxes for
double positive CFSE +/PI + cells). Two-colour Xow cyto-
metric dot plots also showed that incubation with trast-
uzumab induced appreciable tumour cell ADCP compared
to control MOv18 IgG (30.6 vs. 4.9%; Fig. 3b, bottom pan-
els; top right boxes for double positive CFSE +/PE + cells).
Flow cytometric ADCC/ADCP assay measurements con-
Wrmed that trastuzumab at an optimal concentration of
0.5 g/mL mediated signiWcant levels of ADCP of CT26-
HER2/neu tumour cells by monocytic cells. Levels of
ADCP increased »10% above those of the MOv18 IgG and
no antibody controls (Fig. 3c and Supplementary Table II,
Supplementary Data). Statistically signiWcant levels of
ADCC were not measured with any of the conditions tested
here (Supplementary Table II, Supplementary Data). These
data suggest that trastuzumab-IgG1 mediates ADCP, but
not ADCC of tumour cells by monocytic cells.
Cell viability assays demonstrated that CT26-HER2/neu
tumour cells were susceptible to the anti-proliferative eVects
of trastuzumab (IgG1). These eVects were detected after
24 h (89 vs. 96.6% cell viability for trastuzumab and
MOv18 IgG, respectively) and 48 h incubation (87.5 vs.
104.5% cell viability for trastuzumab and MOv18 IgG,
respectively). No cell growth arrest was detected with trast-
uzumab after exposure to antibody for 4 h (104.6 and 100%
viability for trastuzumab and MOv18 IgG, respectively
(Supplementary Fig. 1, Supplementary Data). This con-
Wrmed that tumour cell death measured with the ADCC/
ADCP assays after 3 h exposure to antibodies was not the
result of receptor hetero-dimerisation blocking by trast-
uzumab alone. Thus, the rapid cell death detected by the
ADCC/ADCP assay was most likely mediated by Fc recep-
tors on U937 monocytes in combination with trastuzumab.
The tumour-targeting and phagocytic activities of
trastuzumab measured in the ADCC/ADCP assays were
conWrmed by confocal microscopical imaging (Fig. 3d).
CT26-HER2/neu cells were pre-labelled with CFSE (green),
incubated with U937 cells at and E:T ratio of 2:1, combined
with antibodies, incubated for 3 h on glass chamber slides, and
U937 cells were labelled with anti-CD33-APC mAb (red).
In samples incubated with trastuzumab, enhanced contact
between CT26-HER2/neu tumour cells (green) and U937
monocytic cells (red) was evident, and in many instances two
or more monocytic cells were observed in contact with a sin-
gle tumour cell (Fig. 3d, left, white arrows). We also observed
phagocytosis of tumour cells, clearly visible in the merged
image of the green tumour cells inside the red U937 cells:
most monocytic cells in contact with tumour cells appeared to
contain tumour cell material (Fig. 3d, left; white arrows). In
contrast to these observations, neither contact nor phagocytosis
were observed in samples given MOv18 IgG examined after
3 h in the same culture conditions (Fig. 3d, right). To conWrm
the microscopic observations, the frequency of interactions
between eVector and target cells were measured (Table 3).
Incubation with trastuzumab led to enhanced contact (24.5%
of tumour cells) between tumour and U937 monocytes after
3 h compared to 7.9% contact observed in samples incubated
with MOv18 IgG. Most of the U937 monocytes in contact
with tumour cells contained tumour cell material (20.4% of
tumour cells), suggesting tumour cell phagocytosis, rarely
seen with MOv18 IgG (3.5%). Findings from microscopic
observations and measurements of cell-cell interactions are in
agreement with our ADCC/ADCP assays suggesting that
trastuzumab mediated tumour cell killing by phagocytosis.
Trastuzumab IgE interaction with HER2/neu and IgE 
receptors on monocytic eVector cells and tumour cells
We analysed the interactions of trastuzumab IgE with its
Fc receptors on U937 monocytic cells and with human
Table 2 QuantiWcation of IgE and IgG Receptors on U937 Mono-
cytes
Surface antigen Number of molecules per cell 
(mean § SD) (n = 9)
CD23 2.2 £ 103 § 1.3 £ 103
FcRI 21.8 £ 103 § 4.8 £ 103
FcRI 12.1 £ 103 § 3.9 £ 103
FcRII 19.0 £ 103 § 3.9 £ 103
FcRIII 0.7 £ 103 § 0.4 £ 103123
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76 HER2/neu on the surface of CT26-HER2/neu cells. Trast-
uzumab IgE bound to Fc receptors expressed on the sur-
face of U937 monocytic cells (53.6% of cells) (Fig. 4a,
upper left), in a manner indistinguishable from the positive
control MOv18 IgE (60.6% of cells) (Fig. 4a, upper right).
Lower levels of trastuzumab IgE binding to Fc receptors,
Fig. 3 a Flow cytometric analysis of binding to Fc receptor-express-
ing U937 monocytic cells for trastuzumab (IgG1) (top left) and the chi-
maeric MOv18 IgG antibody against the ovarian cancer antigen FBP
(top right). Flow cytometric analysis of binding to the HER2/neu anti-
gen on the surface of CT26-HER2/neu cells for trastuzumab (bottom
left) and the chimaeric MOv18 IgG antibody against FBP (bottom
right) (Monoclonal antibodies: solid lines; secondary antibody con-
trols: grey histograms). b Trastuzumab-mediated killing of CT26-
HER2/neu tumour cells by U937 monocytes: two-colour Xow cytomet-
ric dot plots detected no ADCC but appreciable ADCP after 2.5 h in
culture. CFSE-labelled tumour cells (x-axis) and dead tumour cells la-
belled with Propidium Iodide (PI) (y-axis), double-positive cells depict
tumour cells killed by ADCC (CFSE+/PI+, upper right boxes, values
are % ADCC) (top). CFSE-labelled tumour cells phagocytosed by
U937 cells labelled with CD89-PE mAb (y-axis, upper left), double
positive cells, CFSE+/PE+ (upper right boxes, values are % ADCP)
(bottom). c QuantiWcation of trastuzumab-mediated CT26-HER2/neu
tumour cell killing by U937 monocytes after 2.5 h using the ADCC/
ADCP assay. Cytotoxicity: black bars; phagocytosis: white bars. Re-
sults are means § SD of six independent experiments. SigniWcance of
values compared to samples given MOv18 IgG (top) or no antibody
(bottom) by the Student’s t test: n/sP > 0.05, *P < 0.05, **P < 0.005,
***P < 0.0005. d Representative confocal Xuorescence images of
CT26-HER2/neu-U937 interactions potentiated by trastuzumab.
CFSE-stained CT26-HER2/neu tumour cells (green) and CD33-APC
labelled U937 cells (red) combined at an original E:T ratio of 2:1 and
incubated for 3 h in culture. U937 cells (red) given trastuzumab IgG
(left) showed enhanced contact with tumour cells (green) and phago-
cytosis of tumour cells (green CFSE inside U937 monocytes, white
arrows). Neither eVector-target cell contact nor phagocytosis was
observed when cells were incubated with control MOv18 IgG antibody
(right). Original magniWcation £63 (scale bar 15 m)123
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77 compared to binding of trastuzumab binding to Fc recep-
tors, are consistent with lower expression of IgE receptors
on U937 cells (Table 2) and our previous Wndings that
MOv18 IgE bound to only a fraction of FcRI receptors on
these cells [30]. Trastuzumab IgE also recognised the
HER2/neu receptor since it bound to 89.3% of CT26-
HER2/neu cells (Fig. 4a, bottom left), similarly, to trast-
uzumab (91.5% cells, Fig. 4a, bottom middle), whilst only
background binding of trastuzumab IgE was detected in
untransfected CT26 cells, which do not express the HER2/
neu receptor (5.2%) (Fig. 4a, bottom right). These data con-
Wrm the speciWcity of the engineered IgE antibody for the
human HER2/neu antigen as well as for the Fc receptors
expressed on the surface of the monocytic cells.
Assessments of the functional properties of trastuzumab 
IgE
Monocytic cells and IgE-mediated tumour cell killing
We wished to assess whether our engineered trastuzumab
IgE was biologically active and thus sought to characterise
its biological properties using two functional assays. One
related to the ability of this antibody to mediate tumour cell
targeting and killing by human eVector cells and was
assessed using our three-colour Xow cytometric ADCC/
ADCP assay. As done above for trastuzumab, the CT26-
HER2/neu cells were used as tumour targets and human
U937 monocytes were employed to provide eVector cells.
Using this method, we observed that incubation of CT26-
HER2/neu and U937 cells with trastuzumab IgE was asso-
ciated with increased tumour cell death by cytotoxicity
(ADCC) (Fig. 4b, c). This was evident by the increased
population of CFSE +/PI + tumour cells in samples incu-
bated with trastuzumab IgE (Fig. 4b, upper right, top right
boxes for CFSE +/PI + tumour cells), compared to those
with the control MOv18 IgE (18.7 vs. 4.6%; Fig. 4b, upper
left). In contrast to trastuzumab, the neither the trastuzumab
nor the MOv18 IgE enhanced the phagocytosis of tumour
cells, as seen in the double positive CFSE +/PE + cell pop-
ulation (4.7 vs. 4.3%; Fig. 4b, bottom panel, top right boxes
for CFSE +/PE + tumour cells). These results also con-
Wrmed that phagocytic killing by trastuzumab and U937
monocytes, measured by the ADCC/ADCP assays (Fig. 3),
were a result of Fc receptor functions of this antibody
rather than non-speciWc uptake of killed tumour cells.
Therefore, Xow cytometric ADCC/ADCP assay mea-
surements conWrmed that trastuzumab IgE, at an optimal
concentration of 0.5 g/mL mediated signiWcant levels of
ADCC of CT26-HER2/neu cells by the monocytic cells
(Fig. 4c). Levels of ADCC increased by »10% above those
of the MOv18 IgE, tested at the same concentrations, and
the no antibody controls (Fig. 4c and Supplementary Table
II, Supplementary Data). Statistically signiWcant levels of
ADCP were not measured in this assay system (P > 0.05;
Supplementary Table II, Supplementary Data). These data
suggest that trastuzumab IgE mediates tumour killing by a
mechanism diVerent from trastuzumab, directing mono-
cytes to act in ADCC instead of ADCP against the tumour
cells.
Interestingly, the antibody concentration (0.5 g/mL)
required to achieve maximum tumour cell killing by mono-
cytes in these assays was the same for IgG and IgE (Fig. 3c,
Fig. 4c and Supplementary Table II, Supplementary Data).
Furthermore, when compared directly in ADCC/ADCP
assays, the two IgE antibodies mediated similar levels of
total tumour cell killing (35% of tumour cells by IgE vs.
36% of tumour cells by IgG; Table 4). Our data show that
IgE is as eVective as IgG in recruiting monocytes to kill
tumour cells in vitro and warrant further studies to compare
the anti-tumour eVector cell functions of these antibodies
in vivo.
Trastuzumab IgE-mediated interactions of monocytic 
and tumour cells
The tumour-targeting activities of trastuzumab IgE mea-
sured in the ADCC/ADCP assays were studied by confocal
microscopical imaging (Fig. 4d). CT26-HER2/neu cells
were pre-labelled with CFSE (green), incubated with U937
cells, combined with antibodies for 3 h on glass chamber
slides, and U937 cells were labelled with anti-CD33-APC
(red). In samples incubated with trastuzumab IgE, contact
between CT26-HER2/neu tumour cells and U937 mono-
cytic cells, was clearly evident, and two or more monocytic
cells were frequently observed in contact with or in close
proximity to a single tumour cell (Fig. 4d, left; white
arrows). However, in contrast to our observations with
Table 3 Microscopic Measurements of CT26-HER2/neu: U937 Cell
Interactions
Data were collected by counting eVector: target cell contact or target
cell phagocytosis per microscopic Weld at a magniWcation of 40£ and
percentage values were calculated. Mean values were calculated from
ten microscopic Welds for each condition and are shown § SD. Stu-
dent’s t test was used to generate signiWcance of values compared to
samples given the corresponding MOv18
n/s P > 0.05; * P < 0.05; ** P < 0.005; *** P < 0.0005
Antibody E:T contact CT26-HER2/neu 
phagocytosis
(mean § SD) (%) (mean § SD) (%)
Trastuzumab (IgG1) 24.5 § 10.5** 20.43 § 9.2***
MOv18 IgG 7.9 § 11.2 3.5 § 5.9
Trastuzumab IgE 29.2 § 13.9*** 4.7 § 5.8 n/s
MOv18 IgE 5.1 § 5.2 2.2 § 5.1123
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78 Fig. 4 a Flow cytometric analysis of binding to IgE receptor-expressing
U937 monocytic cells for trastuzumab IgE (top left) and the chimaeric
MOv18 IgE antibody against the ovarian cancer antigen FBP (top right).
Flow cytometric analysis of trastuzumab IgE (bottom left) and trastuzumab
(IgG1) antibody (bottom middle) binding to the HER2/neu antigen on the
surface of HER2/neu-expressing CT26-HER2/neu cells, and lack of trast-
uzumab IgE binding to HER2/neu-negative CT26 tumour cells (bottom
right). (Monoclonal antibodies: solid lines; secondary antibody controls:
grey histograms). b Trastuzumab IgE-mediated killing of CT26-HER2/
neu tumour cells by U937 monocytes: two-colour Xow cytometric dot
plots detected ADCC but no ADCP after 2.5 h in culture. CFSE-labelled
tumour cells (x-axis) and dead tumour cells labelled with Propidium Iodide
(PI) (y-axis), double-positive cells depict tumour cells killed by ADCC
(CFSE+/PI+, upper right boxes, values are % ADCC) (top). CFSE-labelled
tumour cells phagocytosed by U937 cells labelled with CD89-PE mAb
(y-axis) are double positive CFSE+/PE+ cells (upper right boxes, values
are % ADCP) (bottom). c Quantitation of trastuzumab IgE-mediated
CT26-HER2/neu tumour cell killing by U937 monocytes after 2.5 h using
the ADCC/ADCP assay, at diVerent antibody concentrations. Cytotoxic-
ity: black bars; phagocytosis: white bars. Results are mean § SD of Wve
independent experiments. SigniWcance of values compared to samples giv-
en MOv18 IgE (top) or no antibody (bottom) by the Student’s t test:
n/sP > 0.05, *P < 0.05, **P < 0.005, ***P < 0.0005. d Typical confocal
Xuorescence images of CT26-HER2/neu-U937 interactions potentiated by
trastuzumab IgE. CFSE-stained CT26-HER2/neu tumour cells (green)
and anti-CD33-APC labelled U937 cells (red) combined at an original E:T
ratio of 2:1 and incubated for 3 h in culture. U937 cells (red) given trast-
uzumab IgE (left) exhibited enhanced contact with tumour cells (green)
but no phagocytosis of tumour cells was observed (no green CFSE Xuo-
rescence detected inside U937 cells; white arrows). No eVector-target cell
contact was observed when cells were incubated with control MOv18 IgE
antibody (right). Original magniWcation £63 (scale bar 15 m)123
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79 trastuzumab, trastuzumab IgE did not appear to enhance
phagocytosis, since no green tumour material was observed
inside the red U937 cells (Fig. 4d, left). As expected, rare
contact was observed with the control antibody MOv18
IgE, examined in the same culture conditions (Fig. 4d,
right). Measurements of interactions between eVector and
target cells (Table 3) showed that trastuzumab IgE medi-
ated enhanced eVector: target cell contact (29.2% of tumour
cells) after 3 h, compared to 5.1% contact in samples given
MOv18 IgG. A very small proportion of the U937 mono-
cytes in contact with tumour cells contained tumour cell
material (4.7% of tumour cells), suggesting little tumour
cell phagocytosis was mediated by trastuzumab IgE. Micro-
scopic observations and measurements of eVector: tumour
cell interactions are in agreement with our ADCC/ADCP
assays and are consistent with a role for trastuzumab IgE in
mediating tumour cell death by cytotoxicity.
Trastuzumab IgE activity in mast cell degranulation assays
The second functional assay examined the capacity of trast-
uzumab IgE to stimulate mast cells by way of the high-
aYnity IgE receptor FcRI, and trigger their degranulation.
This is a test of the potency of IgE to activate these eVector
cells, and occurs only following cross-linking of FcRI-
bound IgE by multivalent antigen, by anti-human IgE poly-
clonal antibodies or by antigen-expressing target cells. We
used a previously established system, designed to evaluate
the functional activities of IgE antibodies [48]. The assay
utilises the rat basophilic mast cell line RBL-SX38, trans-
fected to express all four subunits (2) of human FcRI
[48]. Flow cytometric evaluations conWrmed that trast-
uzumab IgE bound to cell surface FcRI of the RBL-SX38
cells (45.3% of cells), similar to the previously character-
ised chimaeric MOv18 IgE (Fig. 5a). To assess the ability
of trastuzumab IgE to cause degranulation of RBL-SX38
cells, we measured -hexosaminidase release upon cell
stimulation and cross-linking by tumour cells (Fig. 5b).
Mast cells alone and mast cells stimulated with trastuzumab
IgE in the absence of cross-linking by anti-IgE antibody,
triggered minimal mast cell degranulation [54]. Mast cells
stimulated with trastuzumab IgE in the presence of anti-IgE
antibody triggered a strong degranulation response
(»40%), compared to negligible degranulation measured
with controls.
We also examined whether the engineered trastuzumab
IgE cross-linked by HER2/neu–expressing tumour cells
was capable of stimulating mast cells in an antigen-dependent
manner. Trastuzumab IgE induced strong degranulation of
RBL-SX38 cells following stimulation with CT26-HER2/
neu cells, which express HER2/neu, whilst untransfected
CT26, which do not express HER2/neu, did not potentiate
-hexosaminidase release (Fig. 5b). Furthermore, CT26-
HER2/neu tumour cells with trastuzumab IgE potentiated
signiWcant -hexosaminidase release that was decreased
proportionally to the decreasing number of tumour cells per
sample. These results clearly demonstrate the functional
activity of trastuzumab IgE-CT26-HER2/neu cells in
triggering mast cell activation and mediator release, and
conWrm that the IgE possesses biological activities that
could be speciWcally directed against HER2/neu-expressing
tumour cells in cancer patients.
Trastuzumab IgE targeting of SKBR3 breast cancer cells
ADCC/ADCP assays using the human breast adenocarci-
noma cell line SKBR3, which naturally express the HER2/
neu antigen, conWrm that trastuzumab and trastuzumab IgE
can focus U937 eVector cells to kill SKBR3 cells (Fig. 6).
As with CT26-HER2/neu cells (Figs. 3, 4), trastuzumab
acted in ADCP of tumour cells (Fig. 6a) whilst trastuzumab
IgE killed by ADCC (Fig. 3b). These Wndings demonstrate
the functional properties of trastuzumab IgE focusing eVec-
tor cell functions against native HER2/neu-expressing
breast tumour cells.
Since trastuzumab (IgG1) can potentiate anti-tumour
eVects by blocking hetero-dimerisation of HER2/neu recep-
tors with other HER family members on the surface of
breast cancer cells, switching oV tumour cell growth signals
[8, 9], the anti-proliferative properties of the engineered
trastuzumab IgE were examined using the MTS cell viabil-
ity assay (Fig. 6c). Neither trastuzumab nor trastuzumab
IgE had any anti-tumour growth eVects after 4 h incubation
with SKBR3 cells (99.3 and 98.6% viability for IgG and
IgE, respectively). Decreased tumour cell viability was
measured after 24 h (88.3 and 83.6% for IgG and IgE,
respectively) and more prominent eVects were measured
after 48 h exposure of tumour cells to the antibodies (72.2
and 64.0% for IgG and IgE, respectively). Control MOv18
IgG and MOv18 IgE antibodies did not aVect SKBR3 cell
viability (mean values ranging from 93.0 to 103.8% viability).
Table 4 % Total tumour cell death by U937 monocytes and antibodies
SigniWcance comparing trastuzumab (IgG1) and trastuzumab IgE to
samples given no antibody (left brackets), MOv18 IgG/IgE (middle
brackets) and signiWcance comparing trastuzumab (IgG1) to trast-
uzumab IgE (right bracket)
Comparisons by the Student’s t test: (n/s)P > 0.05; (*)P < 0.05;
(**)P < 0.005; (***)P < 0.0005
Antibody Tumour cell death § SD 
(n = 6) (%)
No ab 12.5 § 3.1
MOv18 IgG 18.5 § 6.6
Trastuzumab (IgG1) 0.5 g/mL 36.1 § 2.2 (***)(***)
MOv18 IgE 19.8 § 3.2
Trastuzumab IgE 0.5 g/mL 34.8 § 3.5 (***)(***)(n/s)123
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80 These data strongly suggest that trastuzumab IgE possesses
similar properties to trastuzumab in blocking tumour growth
after 24 and 48 h in culture.
Discussion
In our previous studies, we reported the anti-tumour activi-
ties of MOv18 IgE, a chimaeric antibody against the ovar-
ian tumour-associated antigen FBP, compared to the
corresponding antibody of the IgG class [29–32, 49]. Our
studies now form part of a growing body of evidence sug-
gesting that IgE antibodies may have a role in cancer ther-
apy [21–23, 27, 28, 33–35, 55]. The emergence of the
human epidermal growth factor receptor HER2/neu as a
well-validated target for cancer therapeutics [1–4] and the
well-documented but circumscribed success of the human-
ised anti-HER2/neu IgG1 antibody trastuzumab, approved
for the treatment of breast cancer [5–7], rendered the propo-
sition to produce an IgE equivalent moiety timely and rele-
vant in the Weld of biological therapeutics for cancer. For
this, we have engineered a humanised trastuzumab IgE
antibody and here we describe the binding characteristics
and biological properties of this molecule.
The kinetics of antigen binding and cell binding data
suggest that trastuzumab IgE possesses HER2/neu binding
properties that are similar to those observed and measured for
trastuzumab (Table 1; Figs. 2, 3, 4). Similar to other well-
characterised IgE antibodies (MOv18 IgE and NIP IgE),
trastuzumab IgE bound to its high-aYnity receptor FcRI as
expected (Table 1; Figs. 2, 4). Furthermore, using functional
assays, this study demonstrates the biological activity of
trastuzumab IgE antibody in directing eVector cells to target
tumour cells in a tumour antigen-speciWc manner (Figs. 4, 5).
Fig. 5 a Flow cytometric analysis of MOv18 IgE (left) and trast-
uzumab IgE (right) binding to human FcRI receptor-expressing RBL-
SX38 cells. (Monoclonal antibodies: solid lines; secondary antibody
controls: grey histograms). b EVects of trastuzumab IgE cross-linking
on mast cell degranulation. Cells alone or sensitised with trastuzumab
IgE, CT26 tumour cells or CT26-HER2/neu tumour cells at diVerent
concentrations. Trastuzumab IgE was cross-linked with anti-IgE poly-
clonal antibody to conWrm its mast cell degranulation activity. Degran-
ulation was monitored by -hexosaminidase activity released into
culture supernatants in all experiments. Data are mean § SD of three
measurements in a representative of three diVerent experiments with
similar results123
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81 Using our ADCC/ADCP assays and microscopic
images, we made a number of observations relating to the
eVector functions of trastuzumab (IgG1) and trastuzumab
IgE. Trastuzumab triggered appreciable levels of mono-
cyte-mediated tumour cell phagocytosis by human mono-
cytic cells (Figs. 3b, c, 6a), also clearly observed in
confocal images by the presence of tumour cell material
ingested by monocytic cells in contact with tumour cells
(Fig. 3d; Table 3). Whilst the signalling and tumour growth
arrest activities of trastuzumab and their role in its clinical
eYcacy have been the subject of many studies, the anti-
tumour mechanisms relating to eVector cell functions of
trastuzumab have been less extensively investigated [7, 8,
10–14]. ADCC is a known anti-tumour mechanism of
trastuzumab [11, 13, 14]. ADCP is not a widely described
function attributed to trastuzumab, but our data are consis-
tent with ADCP as a potential anti-tumour mechanism for
trastuzumab with human macrophages, as reported by
Lazar et al. [12].
Surprisingly, no trastuzumab-dependent monocyte-
mediated cytotoxicity (ADCC) of tumour cells was detected
above that seen in the controls in our ADCC/ADCP assays.
Using our ADCC/ADCP assay to simultaneously measure
the contributions of ADCC and ADCP [30, 31, 49], we
detected only ADCP killing of tumour cells by trast-
uzumab. There are several possible explanations for the dis-
crepancy between the present results and earlier reports. (1)
Previous assays on the eVector cell functions of trast-
uzumab, in combination with either unfractionated or puri-
Wed human eVector cell populations, did not assess the
contributions of ADCP in the death of tumour cells [11–
14]. It is therefore possible that ADCP-mediated tumour
cell death may have been scored as ADCC if the assays
measured total loss of tumour cells; (2) U937 monocytes
express FcRI and FcRII, but very low levels of FcRIII
(Table 2), and thus it is possible that the absence of appreciable
levels of FcRIII may result in low levels of ADCC [18];
(3) The previously reported tumour cell trastuzumab ADCC
Fig. 6 a Quantitation of 
trastuzumab (IgG1)-mediated 
tumour cell killing of SKBR3 
human breast tumour cells by 
U937 monocytes after 2.5 h 
using the ADCC/ADCP assay. 
b Quantitation of trastuzumab 
IgE-mediated tumour cell killing 
of SKBR3 human breast tumour 
cells by U937 monocytes after 
2.5 h using the ADCC/ADCP 
assay. Cytotoxicity: black bars; 
phagocytosis: white bars. 
Results are means § SD 
of 5 independent experiments. 
SigniWcance of values compared 
to samples given MOv18 IgG/
IgE (top) or no antibody 
(bottom) by the Student’s t test: 
n/sP > 0.05, *P < 0.05, 
**P < 0.005, ***P < 0.0005. 
c Cell viability assays (MTS) 
demonstrating levels of suscepti-
bility of SKBR3 breast cancer 
cells to trastuzumab (IgG1), 
trastuzumab IgE, MOv18 IgG 
and MOv18 IgE antibodies at 4, 
24 and 48 h in culture. Each data 
point represents mean % cell 
viability § SD (n = 4)123
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82 may have been mediated by other IgG receptor-bearing
eVector cells in peripheral blood lymphocytes, such as NK
cells and neutrophils, as previously shown [11–14].
When compared to the FBP-speciWc MOv18 IgE anti-
body in the same assay, trastuzumab IgE activated mono-
cytic eVector cells to exhibit signiWcantly enhanced contact
with tumour cells and to eVectively kill HER2/neu-express-
ing tumour cells (Fig. 4d; Table 3). Trastuzumab IgE
directed monocytes to kill HER2/neu-transfected tumour
cells and also tumour cells naturally-expressing the HER2/
neu antigen by ADCC (cytotoxicity), a mechanism clearly
diVerent from that of the anti-tumour mechanism employed
by trastuzumab in the same assay system (Figs. 3, 4, 6).
This may reXect the speciWc binding of trastuzumab IgE to
the high-aYnity receptor FcRI. Evidence presented in our
previous studies on the mechanism of MOv18 IgE mono-
cyte-mediated tumour cell killing, suggested that binding of
IgE to its high-aYnity receptor FcRI on monocytes trig-
gered tumour cell death by a cytotoxic mechanism, whilst
binding to the low-aYnity receptor CD23 resulted in
tumour cell death by ADCP. U937 monocytes express low
levels of CD23 (»2,200 molecules/cell, Table 2) and, as
observed in our studies with MOv18 IgE, these receptor
levels are too low to mediate ADCP of tumour cells [30].
The function of trastuzumab IgE eVected through CD23
remains to be explored and may reveal additional tumour
cell killing properties of the trastuzumab IgE.
Our assays clearly indicated that the levels of tumour
cell killing mediated by trastuzumab IgE were equivalent to
those by trastuzumab (IgG) at the same optimal doses and
in the same assay system (Figs. 3, 4, Table 4). This was true
despite the relatively low levels of IgE binding on the sur-
face of U937 cells, compared to IgG (Figs. 3a, 4a), in
agreement with previous Wndings [30] suggesting the
potency of IgE-mediated eVector functions [20–23, 27, 28,
35, 56]. IgE has much higher aYnity for FcRI
(Ka = 1010 M¡1) than IgG1 has for any of its three Fc
receptors, especially for FcRIII (Ka = 105 M¡1), the main
receptor associated with tumour cell killing [17, 18, 57].
The relatively high aYnities of the IgE-FcRI interaction
may compensate for the lower binding of IgE on U937
monocytes, resulting in comparable levels of tumour cell
killing. These data clearly indicate the biological function
of trastuzumab IgE in focusing monocytic cells to kill
HER2/neu-expressing tumour cells as eVectively as, but
through a mechanism diVerent from, trastuzumab.
The antibody concentration (0.5 g/mL) required to
achieve maximum tumour cell killing by ADCC/ADCP
was the same for IgG and IgE in our in vitro assays (Figs. 3,
4). In addition, our cell viability data clearly show that
trastuzumab IgE, at concentrations found optimal for eVec-
tor cell responses (0.5 g/mL), maintains the ability to
mediate tumour cell growth arrest over a period of 48 h in
culture and at levels similar to those measured for trast-
uzumab (Fig. 6c). The concentration found optimal for the
in vitro eVector cell functions of trastuzumab IgE was ten-
fold lower than our previously reported optimal concentra-
tions required for MOv18 IgG and IgE-mediated (5 g/mL)
killing of ovarian tumour cells in equivalent in vitro assays
[30–32]. This may suggest that lower levels of trastuzumab
IgE may be required for in vivo activities compared to
those used for MOv18 IgG and MOv18 IgE studies. The
IgE responses measured and observed in our assays support
the conclusion that trastuzumab IgE functions with similar
potency, but through mechanisms diVerent from those of
trastuzumab in vitro, warranting further exploration of this
engineered antibody in more clinically relevant models. It
is possible, however, that trastuzumab IgE may be more
eVective than trastuzumab (IgG1) in vivo for the reasons
cited in the Introduction or that a combination of trast-
uzumab and trastuzumab IgE could have potential synergis-
tic anti-tumour eVects.
We also assessed the potential of the engineered trast-
uzumab IgE to activate other potent IgE receptor-bearing
eVector cells. For this, we have utilised a functional assay
that exempliWes the unique properties of IgE to generate
and enhance immune eVector functions that can be targeted
against cancer cells. Trastuzumab IgE bound to the human
FcRI 2 receptor on the surface of mast cells can be
cross-linked by HER2/neu-expressing tumour cells to trig-
ger mast cell degranulation in an antigen-speciWc manner
(Fig. 5). Tissue mast cell degranulation is a known biologi-
cal property of the IgE antibody class. Mediators released
by degranulated mast cells initiate and potentiate eVector
cell recruitment to the site of tumour antigen challenge,
which can be expected to lead to activation and stimulation
of recruited and locally present eVector cells to act in the
ADCC and ADCP of tumour cells. Mast cell activation by
IgE may thus serve as a potential trigger of a strong, local,
tumour antigen-speciWc IgE immune response against
cancer.
This is the Wrst study describing the properties of an
engineered trastuzumab IgE. Based on the considerable evi-
dence pointing to a number of advantages that IgE may
have in tumour cell surveillance and killing, compared to
IgG, our work points to the importance and value of further
research to investigate the eYcacy and mechanisms of
action of tumour antigen-speciWc antibodies of diVerent
classes, in particular IgE and may help to realise the full
potential of antibodies for immunotherapy of cancer.
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CHAPTER VI 
Summary 
Breast cancer is the most common malignancy in women worldwide. As cancer is a disease 
with increasing prevalence, broad research is going to develop innovative, cost-effective and 
more patient-friendly therapies. Complementary to the standard treatment of breast cancer, 
radiotherapy and chemotherapy, therapeutic approaches have focused on the involvement of 
the immune system. Thereby, the passive application of monoclonal antibodies, such as 
trastuzumab (Herceptin®), targeting the tumour antigen HER-2 on breast cancer cells in a 
highly specific manner became state of the art therapy. Nevertheless, several disadvantages 
and side effects are known.  
As our aim was to improve passive immunotherapy with monoclonal antibodies based on IgE 
antibodies, we applied two different approaches: on the one hand we focused on the 
mimotope strategy, and on the other hand we changed the subclass of the monoclonal 
antibody trastuzumab from IgG to IgE.  
The mimotope approach is well-known in the field of allergology and cancer. A mimotope is 
generated by the phage display technology representing an epitope-mimic of the targeted 
antigen. Active immunization with a mimotope, generated with the anti-HER-2 antibody 
trastuzumab in a biopanning procedure, leads to the production of trastuzumab-like antibodies 
with similar biological functions. As previous studies in our group have focused on the anti-
tumour function of the mimotope-induced IgG antibodies, we were interested in the 
tumouricidal effect of mimotope-induced IgE antibodies.  
Depending on the route of immunization different antibody subclasses are produced. In 
CHAPTER III of this thesis we could show that via oral immunization under acid suppression 
IgE antibodies with high affinity to the antigen are preferable induced. In this study we used 
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the food allergen ovalbumin (OVA) as a model antigen. We have reported that patients treated 
with acid-suppression medication due to dyspeptic disorders produce specific IgE antibodies 
against common dietary antigens. We could confirm that the intake of anti-acid medication 
results in an elevation of the gastric pH with the consequence that digestion-labile proteins 
remain stable, become allergenic and therefore enhance the induction of antigen-specific IgE 
antibodies. We performed comparison studies of different concentrations of OVA and 
different routes of administration. We found out that feedings of OVA alone did not result in 
IgE production at any concentration whereas oral administration of the lowest dose of OVA 
(0.2 mg) under acid-suppression resulted in specific and biologically functional IgE and an 
increase of the Th2 cytokine IL-5. 
Based on this knowledge we combined the mimotope strategy and the oral immunization 
scheme under acid suppression in an anti-cancer study (CHAPTER IV). In a mouse study, 
active vaccination of the HER-2 mimotope via the oral route under simultaneous hypoacidic 
gastric conditions resulted in HER-2-specific IgE production in vivo. To answer the question 
if these IgE antibodies are antigen-specific and biologically active we performed a RBL 
assay. The IgE antibodies binding to FcԑRI on RBL cells were incubated with HER-2 
overexpressing tumour cells. Recognition and binding of IgE to HER-2, led to cross-linking 
of FcԑRI and degranulation of the RBL cells. This reaction was antigen-specific, because 
incubation with a HER-2 negative control cell line did not result in cross-linking and β-
hexosaminidase release. In a next step the cytotoxic potential of the RBL cells as effector 
cells was investigated in an ADCC assay with HER-2 overexpressing tumour cells as target 
cell line. Mimotope-induced IgE antibodies led to lysis of 20% to 100% of tumour cells in a 
highly specific manner. This study clearly demonstrated the active induction of tumour-
specific IgE led to killing of the tumour cells by cross-linking of FcԑRI on potent effector 
cells, such as RBL cells. 
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Furthermore, to directly compare the anti-tumour effects of IgG and IgE we generated an IgE 
analogue of trastuzumab as described in CHAPTER V. To prove whether the newly 
engineered IgE antibody recognizes HER-2 and the IgE receptors we performed kinetic 
studies using surface plasmon resonance analysis. Besides, the binding characteristic of 
trastuzumab IgG and IgE was investigated on the monocytic cell line U937 and on HER-2 
overexpressing tumour cells by flow cytometry. These cell lines served in the subsequent 
killing experiment as effector and target cells. Our results confirmed that trastuzumab IgE 
bound to HER-2 comparable to trastuzumab IgG. Moreover, trastuzumab IgE bound to the 
high affinity IgE receptor comparable to other control IgE antibodies. The next step was to 
assess the biological activity and the comparison of trastuzumab IgE and IgG in respect of 
their tumor cell killing mechanism in a three-colour flow cytometric ADCC/ADCP assay. We 
could demonstrate that IgE is as effective as IgG in recruiting monocytes to kill tumour cells 
in vitro. In contrast to an unspecific control IgE antibody we observed that incubation of 
trastuzumab IgE, U937 cells and HER-2 positive target cells was associated with increased 
tumour cell death by cytotoxicity (ADCC), whereas trastuzumab IgG killed by phagocytosis 
(ADCP). In a RBL assay, incubation of trastuzumab IgE with HER-2 overexpressing cells led 
to mast cell activation and mediator release. Furthermore, we were interested in the anti-
proliferative properties of trastuzumab IgE compared to its IgG analogue. Therefore we 
performed a cell viability assay and observed that after 24 h and 48 h incubation of IgE and 
IgG growth of HER-2 positive tumour cells was inhibited with a similar percentage. 
From the results presented in this thesis we conclude that there is evidence that IgE antibodies 
directed against tumour antigens, either applied in an active or passive manner, are efficient in 
mediating tumour cell killing.  
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